<SEC-DOCUMENT>0001104659-20-025053.txt : 20200226
<SEC-HEADER>0001104659-20-025053.hdr.sgml : 20200226
<ACCEPTANCE-DATETIME>20200226080221
ACCESSION NUMBER:		0001104659-20-025053
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200226
DATE AS OF CHANGE:		20200226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-220942
		FILM NUMBER:		20653344

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm209716-1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333-220942</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #DE1A1E"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus Supplement<BR>
(To Prospectus Dated November 21, 2017)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="tm209716-1_424b5img01.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,084,034 Class A Units each consisting
of one Share of Common Stock and&nbsp;one-half of one Common Stock Purchase Warrant </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(and 5,042,017 Shares of Common Stock
Issuable Upon Exercise of the Common Stock Purchase Warrants)</B>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering directly to selected investors 10,084,034&nbsp;Class
A Units, with each Class A Unit consisting of one share of our common stock, par value $0.0001 per share and&nbsp;one-half of one
warrant to purchase shares of our common stock, referred to herein as a common stock purchase warrant, at an exercise price of
$0.53&nbsp;per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NASDAQ Capital Market under
the symbol &ldquo;LPCN.&rdquo; On February 24, 2020, the last reported sale price of our common stock on the NASDAQ Capital Market
was $0.77 per share. There is no established public trading market for the common stock purchase warrants, and we do not expect
a trading market to develop. Without an active trading market, the liquidity of the warrants will be limited. In addition, we do
not intend to apply for listing of the common stock purchase warrants on any securities exchange or recognized trading system.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus supplement and the accompanying
prospectus and the documents incorporated by reference in this prospectus supplement carefully before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk.
See &ldquo;Risk Factors&rdquo; beginning on page S-15 of this prospectus supplement, &ldquo;Risk Factors&rdquo; beginning on page&nbsp;5
of the accompanying prospectus, the &ldquo;Risk Factors&rdquo; section beginning on page 19 of our Annual Report on Form 10-K for
the year ended December 31, 2018, the &ldquo;Risk Factors&rdquo; section beginning on page 33 of our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2019, the &ldquo;Risk Factors&rdquo; section beginning on page 34 of our Quarterly Report on Form
10-Q for the quarter ended June 30, 2019, the &ldquo;Risk Factors&rdquo; section beginning on page 36 of our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2019, and under similar headings in the other documents that are filed after the
date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus
supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Class A Unit (one share of common<BR> stock, and one-half of one common stock<BR> purchase warrant)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; font-size: 10pt">Public offering price</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">0.595000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">6,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Placement Agent&rsquo;s fees (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.032725</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">330,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds, before expenses, to us (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.562275</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,670,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-size: 10pt">We have agreed to pay the placement agent a commissions equal to 5.5% of the gross proceeds from this offering. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We estimate the total expenses of this offering payable by us, excluding the Placement Agent&rsquo;s fees, will be approximately $45,000.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged Roth Capital Partners, LLC as our exclusive
placement agent to use its reasonable best efforts to solicit offers to purchase the Class A Units in this offering. The Placement
Agent has no obligation to buy any shares of common stock or common stock purchase warrants from us or to arrange for the purchase
or sale of any specific number or dollar amount of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery of the securities will be made against payment thereon
on or about February 27, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Roth Capital Partners</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
February 25, 2020.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt; text-transform: uppercase">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">S-i</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt; text-transform: uppercase">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">S-ii</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt; text-transform: uppercase">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-1</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt; text-transform: uppercase">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-13</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt; text-transform: uppercase">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-15</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-31</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt; text-transform: uppercase">CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt; text-transform: uppercase">s-32</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-33</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF SECURITIES WE ARE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-34</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt; text-transform: uppercase">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-35</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt; text-transform: uppercase">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-37</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt; text-transform: uppercase">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-37</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-size: 10pt; text-transform: uppercase">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-37</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014"><FONT STYLE="font-size: 10pt; text-transform: uppercase">INCORPORATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014"><FONT STYLE="font-size: 10pt; text-transform: uppercase">S-37</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#a_016"><FONT STYLE="font-size: 10pt; text-transform: uppercase">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">i</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017"><FONT STYLE="font-size: 10pt; text-transform: uppercase">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">ii</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_018"><FONT STYLE="font-size: 10pt; text-transform: uppercase">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_019"><FONT STYLE="font-size: 10pt; text-transform: uppercase">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_020"><FONT STYLE="font-size: 10pt; text-transform: uppercase">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_021"><FONT STYLE="font-size: 10pt; text-transform: uppercase">RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK DIVIDENDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_021"><FONT STYLE="font-size: 10pt; text-transform: uppercase">7</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_022"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_022"><FONT STYLE="font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_023"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_023"><FONT STYLE="font-size: 10pt">12</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_024"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_024"><FONT STYLE="font-size: 10pt; text-transform: uppercase">13</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_025"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_025"><FONT STYLE="font-size: 10pt; text-transform: uppercase">15</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_026"><FONT STYLE="font-size: 10pt; text-transform: uppercase">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_026"><FONT STYLE="font-size: 10pt">16</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_027"><FONT STYLE="font-size: 10pt; text-transform: uppercase">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_027"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_028"><FONT STYLE="font-size: 10pt; text-transform: uppercase">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_028"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_029"><FONT STYLE="font-size: 10pt; text-transform: uppercase">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_029"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_030"><FONT STYLE="font-size: 10pt; text-transform: uppercase">INCORPORATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_030"><FONT STYLE="font-size: 10pt">20</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">References in this prospectus supplement,
the accompanying prospectus and the documents incorporated by reference to the &ldquo;Company,&rdquo; &ldquo;Lipocine,&rdquo; &ldquo;our,&rdquo;
 &ldquo;us&rdquo; or &ldquo;we&rdquo; refer to Lipocine Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This document is in two parts. The first
part is this prospectus supplement, which describes the specific terms of this offering and certain other matters. The second part,
the accompanying prospectus, provides more general information about us and our common stock. Generally, when we refer to the prospectus,
we are referring to both parts of this document combined. To the extent information in this prospectus supplement conflicts with
information in the accompanying prospectus, you should rely on the information in this prospectus supplement. You should rely only
on the information contained in, or incorporated by reference in, this prospectus supplement and the accompanying prospectus and
any related &ldquo;free writing prospectus.&rdquo; None of the Company or the placement agent has authorized anyone to provide
information different from that contained in, incorporated or deemed incorporated by reference into this prospectus supplement
or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">We
note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some
cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.
Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state
of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before you invest, you should read the registration
statement of which this document forms a part, this document, the accompanying prospectus and the documents incorporated by reference
herein that are described under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this document may only
be accurate on the date of the document. You should assume that the information appearing in this prospectus supplement is accurate
only as of the date on the front cover of this prospectus supplement. Our business, financial condition, results of operations
and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not making an offer of these securities
in any jurisdiction where the offer is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement contains summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which
this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading &ldquo;Where
You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement, the accompanying
prospectus, and the documents incorporated by reference contain forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks
and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include
any statement that does not directly relate to any historical or current fact. Forward-looking statements are based on our management&rsquo;s
current beliefs, expectations and assumptions about future events, conditions and results and on information currently available
to us. Discussions containing these forward-looking statements may be found, among other places, in the Sections of this prospectus
supplement entitled &ldquo;Prospectus Summary&rdquo; and &ldquo;Risk Factors.&rdquo; See also &ldquo;Special Note Regarding Forward-Looking
Statements&rdquo; in the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All statements, other than statements of
historical fact, included or incorporated herein regarding our strategy, future operations, financial position, future revenues,
projected costs, plans, prospects and objectives are forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
 &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions. These statements involve risks, uncertainties
and other factors that may cause our actual results, performance, time frames or achievements to be materially different from any
future results, performance, time frames or achievements expressed or implied by the forward-looking statements. Risks, uncertainties
and other factors that might cause or contribute to such differences include, but are not limited to, the risks described in this
prospectus supplement and detailed in Lipocine&rsquo;s filings with the Securities and Exchange Commission (&ldquo;SEC&rdquo;),
including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website
at www.sec.gov. Given these risks, uncertainties and other factors, many of which are beyond our control, you should not place
undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, past financial and/or operating
performance is not necessarily a reliable indicator of future performance and you should not use our historical performance to
anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking
statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Except
as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking
statements to reflect events or developments occurring after the date of this prospectus supplement, even if new information becomes
available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: 0in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary is not complete and does
not contain all of the information that you should consider before investing in the securities offered by this prospectus supplement
and the accompanying prospectus. You should carefully read this prospectus supplement and the accompanying prospectus, including
the documents we incorporate by reference, to understand fully our common stock as well as other considerations that are important
to you in making a decision to invest in our common stock. You should pay special attention to the &ldquo;Risk Factors&rdquo; section
beginning on page S-15 of this prospectus supplement, the &ldquo;Risk Factors&rdquo; section beginning on page 5 of the accompanying
prospectus, the &ldquo;Risk Factors&rdquo; section beginning on page 19 of our Annual Report on Form 10-K for the year ended December
31, 2018, the &ldquo;Risk Factors&rdquo; section beginning on page 33 of our Quarterly Report on Form 10-Q for the quarter ended
March 31, 2019, the &ldquo;Risk Factors&rdquo; section beginning on page 34 of our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2019 and the &ldquo;Risk Factors&rdquo; section beginning on page 36 of our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019, each of which is incorporated by reference in this prospectus supplement along with our consolidated
financial statements and notes to those consolidated financial statements and the other information incorporated by reference in
this prospectus supplement and the accompanying prospectus to determine whether an investment in our common stock is appropriate
for you. This prospectus supplement and the accompanying prospectus include forward-looking statements that involve risks and uncertainties.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Summary of Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company focused on applying our oral drug delivery technology for the development of pharmaceutical products focusing on metabolic
and endocrine disorders. Our proprietary delivery technologies are designed to improve patient compliance and safety through orally
available treatment options. Our primary development programs are based on oral delivery solutions for poorly bioavailable drugs.
We have a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (&ldquo;PK&rdquo;) characteristics
and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal
interactions that limit bioavailability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our most advanced product candidate,
TLANDO&trade;, is an oral testosterone replacement therapy (&ldquo;TRT&rdquo;). On November 8, 2019 we received a Complete Response
Letter (&ldquo;CRL&rdquo;) from the United States Food and Drug Administration (&ldquo;FDA&rdquo;) regarding our New Drug Application
(&ldquo;NDA&rdquo;) filed in May 2019 for TLANDO as a TRT in adult males for conditions associated with a deficiency of endogenous
testosterone, also known as hypogonadism. A CRL is a communication from the FDA that informs companies that an application cannot
be approved in its present form. The CRL identified one deficiency stating the efficacy trial did not meet the three secondary
endpoints for maximal testosterone concentrations (&ldquo;Cmax&rdquo;). The CRL did not identify any specific issues relating to
chemistry, manufacturing and controls (&ldquo;CMC&rdquo;) of TLANDO. We had our Post Action meeting with the FDA in January 2020
and discussed a potential path forward for the approval of TLANDO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additional pipeline candidates include
LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU for the treatment of pre-cirrhotic non-alcoholic steatohepatitis
(&ldquo;NASH&rdquo;), TLANDO XR (LPCN 1111), a next generation oral TRT product with the potential for once daily dosing which
has completed Phase 2 testing, LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of NASH cirrhosis, and
LPCN 1107, potentially the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth,
which has completed an End-of-Phase 2 meeting with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">LPCN 1144 is currently being tested
in the <I>LiFT</I> (&ldquo;Liver Fat intervention with oral Testosterone&rdquo;) Phase 2 clinical study, a paired-biopsy study
in confirmed pre-cirrhotic NASH subjects. Additionally, LPCN 1144 recently completed a Proof-Of-Concept (&ldquo;POC&rdquo;) liver
imaging clinical study which demonstrated substantial liver fat reductions in hypogonadal males at risk of developing NASH as assessed
using magnetic resonance imaging, proton density fat fraction (&ldquo;MRI-PDFF&rdquo;) technique.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have funded our operations primarily
through the sale of equity securities, debt and convertible debt and through up-front payments, research funding and royalty and
milestone payments from our license and collaboration arrangements. We have not generated any revenues from product sales and we
do not expect to generate revenue from product sales unless and until we obtain regulatory approval of TLANDO or other products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred losses in most years since
our inception. As of September 30, 2019, we had an accumulated deficit of $147.8 million. Income and losses fluctuate year to year,
primarily depending on the nature and timing of research and development occurring on our product candidates. Our net loss was
$9.7 million for the nine months ended September 30, 2019, compared to $8.4 million for the nine months ended September 30, 2018.
Substantially all of our operating losses resulted from expenses incurred in connection with our product candidate development
programs, our research activities and general and administrative costs associated with our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to continue to incur significant
expenses and operating losses for the foreseeable future as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">conduct any other pre-approval clinical studies required in support of TLANDO;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">conduct further development of our other product candidates, including LPCN 1144;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">continue our research efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">research new products or new uses for our existing products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">maintain, expand and protect our intellectual property portfolio; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">provide general and administrative support for our operations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To fund future long-term operations, we
will need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including
capital market conditions, regulatory requirements and outcomes related to TLANDO as outlined in our most recent CRL, regulatory
requirements related to our other product development programs, the timing and results of our ongoing development efforts, the
potential expansion of our current development programs, potential new development programs, our ability to license our products
to third parties, the pursuit of various potential commercial activities and strategies associated with our development programs
and related general and administrative support. We anticipate that we will seek to fund our operations through public or private
equity or debt financings or other sources, such as potential license, partnering and collaboration agreements. We cannot be certain
that anticipated additional financing will be available to us on favorable terms, or at all. Although we have previously been successful
in obtaining financing through public and private equity securities offerings and our license and collaboration agreements, there
can be no assurance that we will be able to do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Industry </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Testosterone Background </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Testosterone, or T, is the primary circulating
sex hormone in males and is critical to the development and maturation of reproductive tissues as well as other secondary male
characteristics such as muscle growth and bone density. Synthesized in the gonads of both males (testis) and females (ovaries),
testosterone circulates bound to sex hormone binding globulin (&ldquo;SHBG&rdquo;, ~60%), loosely bound to albumin, a protein in
the blood that binds to testosterone (~40%), or as a free molecule (~1%). Once circulating, testosterone enters cells directly
and activates a network of proteins that ultimately result in metabolic conversions, which in turn produce observable effects.
The concentration of circulating testosterone can vary drastically over time or between individuals and can be dependent on genetic
factors, other medical conditions, lifestyle behaviors, and/or concurrent medication administration. Although large variability
exists, the effects of testosterone are also determined by a number of factors including the amount of steroid penetration, sensitivity
of enzymes and cellular proteins to the hormone, and the action of genomic receptors at the cellular level. As a result, assessing
clinically low, or potentially high, levels of naturally occurring testosterone often requires a number of quantitative tests in
conjunction with clinical evaluations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Hypogonadism Overview </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Low serum testosterone causes significant
clinical impact and can result in erectile dysfunction, low libido, decreased muscle mass and strength, increased body fat, decreased
bone density, decreased vitality and depressed mood. Furthermore, low serum testosterone concentrations have been found to be an
independent predictor of a number of cardiovascular risk factors including obesity, abnormal lipid levels, hypertension, type 2
diabetes, and systemic inflammation. Well-designed, prospective clinical trials have determined that low testosterone levels are
also independently associated with mortality risk. These findings have generated interest amongst the medical community and general
public regarding the importance of maintaining appropriate serum testosterone levels, which has stimulated growth of the testosterone
replacement therapy market which peaked in 2013. The testosterone therapy market contracted in 2014 due to a number of factors
including the withdrawal of direct to consumer advertising mid-2014 but has seen year-over-year growth since 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hypogonadism typically refers to a permanent
deficiency of sex hormones rather than a temporary deficiency that may be related to acute/chronic illnesses or other medical,
personal, or environmental factors. Primary hypogonadism describes disease states that intrinsically affect the gonads. Examples
of these include the genetic disorders, Turner syndrome and Kleinfelter syndrome. Secondary hypogonadism refers to disease states
that affect gonadal-related structures such as the hypothalamus and pituitary gland that directly impact the development of gonads
and as such the release of testosterone and other sexual hormones. Kallmann syndrome, in which patients fail to undergo all of
the changes associated with puberty, is a type of secondary hypogonadism. Although a number of inherited diseases are known to
affect the gonads either directly or indirectly, it is generally believed that the majority of individuals with hypogonadism develop
the condition as a result of age-related declines in testosterone or other acquired conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Diagnosis and Treatment of Hypogonadism </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Epidemiological studies have determined
that total testosterone follows an age-related decline with mean serum concentration at the age of 75 years approximately two thirds
that at 25 years. Because naturally occurring testosterone exists at low concentrations, with normal testosterone levels in the
range of 300 to 1100 ng/dL automated platform-based assays have been found to lack specificity and are prone to inter-lab variability.
The lack of reliable laboratory tests is complicated further by the inter-individual variability seen in an unaffected population.
Thus, in order to accurately diagnose hypogonadism in a male, at least two morning serum testosterone levels are performed in conjunction
with a clinical assessment of patient symptoms. Patients can only be diagnosed when they present with symptoms that are directly
related to low morning serum testosterone level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Treatment for male hypogonadism (both primary
and secondary) is testosterone replacement therapy, or TRT. Some of the reported benefits of TRT include improved libido and sexual
function; increased bone density, muscle development, and cognition; as well as a reduction in other risk factors caused by low
testosterone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Testosterone Replacement Market </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due to the wide variability in therapeutic
range and other medical conditions that may confound an accurate diagnosis, there is a consensus that male hypogonadism is significantly
undertreated. A large study of 1,475 men between the ages of 30 and 79 years old revealed that the prevalence of hypogonadism is
about 24%. Based on this prevalence rate and the U.S. Census Bureau&rsquo;s 2017 estimate that there are 90.4 million men between
30 years old and 79 years old, approximately 21.7 million men in the U.S. may have low testosterone. In the study fewer than 4%
of patients were receiving treatment for hypogonadism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Testosterone replacement therapies have
been commercially available in the United States for over 70 years and have followed a progression of delivery systems that included
subcutaneous, or under-the-skin, injection, intramuscular injection, transdermal patch, and finally topical gels, which initially
surfaced in 2000, and creams. In 2018, a weekly subcutaneous-delivery system for testosterone was approved. The difficulty in creating
an easy to use/administer and clinically effective testosterone therapy is related to the molecule&rsquo;s complex pharmacokinetics.
Pharmacokinetics, or PK, describe how the body affects a specific drug after administration through the mechanism of absorption
and distribution, as well as the chemical changes of the substance in the body. For example, oral therapies, which would ideally
be the most popular route of delivery, require multiple, high daily doses due to low bioavailability. Bioavailability is the fraction
of a drug dose that is actually absorbed into the bloodstream. Additionally, the few oral therapies that have been used in the
United States previously quickly went out of favor after significant side effects were revealed, most notably liver toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, the U.S. TRT market consists
of therapies that exist in four forms:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 12.95pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>gel/patch;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 12.95pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>injectable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 12.95pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>intranasal; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 12.95pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>buccal tablet, which is a tablet shaped patch applied to the upper gums.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although transdermal patches were previously
the most desirable application type, gel-based TRT has gained increasing popularity due to improved skin tolerability. Despite
becoming a popular approach to male hypogonadism treatment, topical gels are not without limitations. Topical gels place women
and children at risk of testosterone transference (secondary exposure to gels), which has prompted the FDA to add black box warnings
relating to testosterone transference in the label of approved topical products. Despite these limitations, gels have continued
to demonstrate significant market penetration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The male testosterone market was $1.7 billion
in 2018 according to IMS Health data. Additionally, testosterone replacement prescriptions were approximately 7.3 million in 2018
according to IMS Health data. Injectables are the predominant dosage form in this market in terms of annual prescriptions written
although topical gels garner the majority of the dollar sales and also have a significant share of total annual prescriptions.
The historical growth in the market was driven by increasing recognition by both patients and providers of the prevalence of hypogonadism
and its far-reaching medical consequences. Top treatments are marketed by AbbVie Inc. (&ldquo;AbbVie&rdquo;) and Endo Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Product Candidates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our current portfolio includes
our most advanced product candidate, TLANDO, an oral testosterone replacement therapy product candidate, which received a CRL on
November 8, 2019. Additionally, we are in the process of establishing our pipeline of other clinical candidates including an oral
androgen therapy for the treatment of pre-cirrhotic NASH, LPCN 1144, a next-generation potential once daily oral testosterone replacement
therapy, TLANDO XR (LPCN 1111), an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the
prevention of preterm birth, LPCN 1107.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These products are based on our proprietary
Lip&rsquo;ral drug delivery technology platform. Lip&rsquo;ral technology is a patented technology based on lipidic compositions
which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs. The drug
loaded dispersed phase presents the solubilized drug efficiently at the absorption site (gastrointestinal tract membrane) thus
improving the absorption process and making the drug less dependent on physiological variables such as dilution, gastro-intestinal
pH and food effects for absorption. Lip&rsquo;ral based formulation enables improved solubilization and higher drug-loading capacity,
which can lead to improved bioavailability, reduced dose, faster and more consistent absorption, reduced variability, reduced sensitivity
to food effects, improved patient compliance, and targeted lymphatic delivery where appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TLANDO: An Oral Product Candidate for Testosterone Replacement
Therapy </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our most advanced product, TLANDO, is an
oral formulation of the chemical, TU, which is an eleven carbon side chain attached to T. TU is an ester prodrug of T. An ester
is chemically formed by bonding an acid and an alcohol. Upon the cleavage, or breaking, of the ester bond, T is formed. TU has
been approved for use outside the United States for many years for delivery via intra-muscular injection and in oral dosage form
and recently TU has received regulatory approval in the United States for delivery via intra-muscular injection. We are using our
proprietary technology to facilitate steady gastrointestinal solubilization and absorption of TU. Proof of concept was initially
established in 2006, and subsequently TLANDO was licensed in 2009 to Solvay Pharmaceuticals, Inc. which was then acquired by Abbott
Products, Inc. (&ldquo;Abbott&rdquo;). Following a portfolio review associated with the spin-off of AbbVie by Abbott in 2011, the
rights to TLANDO were reacquired by us. All obligations under the prior license agreement have been completed except that Lipocine
will owe Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $1 million in the first two calendar years following
product launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any
such product are introduced, then royalties are reduced by 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>NDA PDUFA Outcome</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 8, 2019 we received
a CRL from the FDA regarding our NDA filed in May 2019 for TLANDO as a TRT in adult males for conditions associated with a deficiency
of endogenous testosterone, also known as hypogonadism. The CRL identified one deficiency stating the efficacy trial did not meet
the three Cmax secondary endpoints. The CRL does not identify any specific issues relating to CMC of TLANDO. We had a Post Action
meeting with the FDA in January 2020 and discussed a potential path forward for the approval of TLANDO. Previously, we have received
two other CRL&rsquo;s from the FDA on TLANDO NDA submissions. The first CRL was received on June 28, 2016 and the second CRL was
received on May 8, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Results from the ABPM Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ABPM Study was an open label,
single arm study that enrolled 144 male hypogonadal subjects undergoing four months of treatment with TLANDO, 225 mg BID dosing,
with 24-hour blood pressure measurements taken at baseline and at the end of the study. There were 138 subjects who received at
least one dose of study drug and 126 subjects completed the study. There were 118 subjects enrolled in the ABPM Study with evaluable
weighted average 24-hour ABPM data at both baseline and at the end of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subjects receiving treatment in the ABPM Study had following
baseline parameters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left; padding-left: 53pt">Baseline Parameters</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mean (SD)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Age (years) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53.8 (10.2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">BMI (kg/m2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">33.1 (5.8)</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">24h SBP (mm Hg)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">127 (16)</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">24h DBP (mm Hg)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">79 (6)</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>SD = Standard Deviation, BMI = Body Mass
Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, among the subjects enrolled
in the ABPM Study, 48% of the subjects were hypertensive and 24% of subjects were type 2 diabetic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Top-line results from the ABPM Study are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 4pt; text-align: center"><FONT STYLE="font-size: 10pt">Parameter</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Mean Change, mm Hg (95% CI)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; background-color: #CCEEFF; text-align: center"><FONT STYLE="font-size: 10pt">24-hour SBP</FONT></TD>
    <TD STYLE="width: 1%; border-top: #CCEEFF 1pt solid; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 38%; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">3.82 (1.69, 5.96)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">24-hour DBP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.20 (0.31, 2.08)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -1in; text-align: center"><I>CI = Confidence Interval, SBP = Systolic
Blood Pressure, DBP = Diastolic Blood Pressure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Of the subjects (n=25) with baseline
24-hour average systolic blood pressure (&ldquo;SBP&rdquo;) greater than 140 mm Hg, 32% of the subjects were less than or equal
to 140 mm Hg at the end of study. Additionally, of the subjects (n=93) with baseline 24-hour average SBP of less than or equal
to 140 mm Hg, 9.7% of the subjects were greater than 140 mm Hg at the end of study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 0"><I>Results from the Definitive Phlebotomy Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The definitive phlebotomy study
was designed based on the FDA&rsquo;s protocol recommendations and conducted in response to a deficiency cited in the TLANDO CRL
by the FDA to confirm the reliability of TLANDO Phase 3 study results and to assess the impact of any material deviation from instructions
on sample collection/processing times by clinical sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The definitive phlebotomy
study measured testosterone concentrations in blood samples collected in plain serum separation tubes (&ldquo;SST&rdquo;) at three-hour
and five-hour time points (N=24) post dose and processed within 30 minutes of sample collection under the tube manufacturer&rsquo;s
recommended conditions and consistent with Phase 3 instructions. The definitive phlebotomy study enrolled 12 hypogonadal male subjects
and dosed subjects with a single oral 225 mg TU dose of TLANDO. The testosterone measurements in SST were compared against the
FDA&rsquo;s recommended time zero control (processed immediately) measurement of testosterone concentrations in blood samples in
plasma tubes with EDTA (&ldquo;PT&rdquo;) to assess ex vivo conversion, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The top-line results
of the definitive phlebotomy study demonstrated that the overall (N=24) mean percentage difference and the associated percentage
standard deviation post dose of testosterone concentrations measured between SST samples and PT samples are -1.0% and 9.2%, respectively.
This difference was not statistically significant (p = 0.91) which suggests no significant ex vivo TU to T conversion occurrence
with T measurements processed within 30 minutes of sample collection under the SST manufacturer&rsquo;s recommended conditions
and consistent with Phase 3 instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Results from DV and DF Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The DV and
DF studies were both an open-label, fixed dose (no titration), single treatment clinical study of oral TRT in hypogonadal males
with low testosterone (T) (&lt; 300 ng/dL) that assessed TLANDO in hypogonadal males on a fixed daily dose of 450 mg divided into
two equal doses (&ldquo;BID&rdquo;) in the DV study and into three equal doses (&ldquo;TID&rdquo;) in the DF study. In total, 95
and 100 subjects were enrolled into DV and DF studies, respectively, with 94 and 98 subjects completing the DV and DF studies,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the results from the
DV study confirm the validity of a fixed dose approach without the need for dose titration to orally administering TLANDO although
there is no guarantee of FDA approval of TLANDO. The DV study is considered our pivotal efficacy clinical study. TLANDO successfully
met the FDA primary efficacy guidelines in the DV study safety statistical analysis set (&ldquo;SS&rdquo;) where 80% of the subjects
achieved average testosterone levels (&ldquo;Cavg&rdquo;) within the normal range with a lower bound confidence interval (&ldquo;CI&rdquo;)
of 72%. The DF study restored 70% of the subjects&rsquo; average testosterone levels within the normal range (Cavg) confirming
that twice daily (&ldquo;BID&rdquo;) dosing is the appropriate dosing regimen for TLANDO and was the basis for resubmission. The
safety set is defined as any subject that was randomized into the study and took at least one dose (N=95 subjects in the DV study
and N=100 in the DF study). A baseline carried forward approach was used to account for missing data as a result of subject discontinuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The primary efficacy endpoint is
the percentage of subjects with Cavg within the normal range, which is defined as 300-1080 ng/dL. The FDA guidelines for primary
efficacy success is that at least 75% of the subjects on active treatment achieve a testosterone Cavg within the normal range;
and the lower bound of the 95% CI must be greater than or equal to 65%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The adverse
event profile of TLANDO in both the DV and DF studies was consistent with the previously conducted 52-week Phase 3 Study of Androgen
Replacement (&ldquo;SOAR&rdquo;) clinical trial. All drug related adverse events (&ldquo;AEs&rdquo;) were either mild or moderate
in intensity and none were severe. To date, the safety database of TLANDO includes ~591 subjects demonstrating a profile consistent
with other TRT products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The secondary
endpoints assessed the maximum total testosterone concentration (&ldquo;Cmax&rdquo;) post dosing using predetermined limits developed
by the FDA for transdermals. The FDA guidelines for secondary efficacy success is that at least 85% of the subjects achieve Cmax
less than 1500 ng/dL; no greater than 5% of the subjects have Cmax between 1800 ng/dl and 2500 ng/dL; and zero percent of the subjects
have Cmax greater than 2500 ng/dL. Consistent with the definition of Cmax and the pharmacokinetic profile of multiple times a day
dosing, two pre-specified analyses were performed, Cmax per dose and Cmax per day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the DV study SS Cmax per dose
analysis, the percentage of subjects with Cmax less than 1500 ng/dL and between 1800 ng/dL and 2500 ng/dL were 85% and 7%, respectively.
Deviations from the predetermined limits in the DV study were observed in the Cmax per day dose analysis for these thresholds.
As such, this efficacy trial did not meet the three Cmax per day secondary endpoints. Only one subject, who was a major protocol
violator, exceeded the 2500 ng/dL limit independent of per dose or per day dose analyses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The DF study SS met all Cmax thresholds in per dose
and per day dose analyses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to conducting the DV study
and the DF study, we completed our SOAR pivotal Phase 3 clinical study evaluating efficacy and 52-week safety of TLANDO. The SOAR
study is considered our pivotal safety clinical study for the NDA resubmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0; text-indent: 0.45in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0"><I>Results from SOAR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SOAR was a randomized, open-label, parallel-group,
active-controlled, Phase 3 clinical study of TLANDO in hypogonadal males with low testosterone (&lt; 300 ng/dL). In total, 315
subjects at 40 active sites were assigned, such that 210 were randomized to TLANDO and 105 were randomized to the active control,
AndroGel 1.62%&reg;, for 52 weeks of treatment. The active control is included for safety assessment. TLANDO subjects were started
at 225 mg TU (equivalent to ~ 142 mg of T) twice daily (&ldquo;BID&rdquo;) with a standard meal and then dose titrated, if needed,
based on average T levels during the day, Cavg, and peak serumT levels, Cmax, up to 300 mg TU BID or down to 150 mg TU BID based
on serum testosterone measured at weeks 3 and 7 based on PK profile with multiple blood samples drawn at each time period. The
mean age of the subjects in the trial was ~53 years with ~91% of the patients &lt; 65 years of age. The discontinuation rate for
TLANDO was 38% compared to 32% for AndroGel 1.62%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-indent: 0.45in">Primary statistical analysis was
conducted using the Efficacy Population Set (&ldquo;EPS&rdquo;). The EPS is defined as subjects randomized into the study with
at least one PK profile and no significant protocol deviations and includes imputed missing data by last observation carried forward,
N=151. Further analysis was performed using the full analysis set (&ldquo;FAS&rdquo;) (any subject randomized into the study with
at least one post-baseline efficacy variable response, N=193) and the SS (any subject that was randomized into the study and took
at least one dose, N=210).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Safety</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.45in">The safety component of the SOAR
trial was completed the last week of April 2015. The safety extension phase was designed to assess safety based on information
such as metabolites, biomarkers, laboratory values, serious adverse events SAEs and AEs, with subjects on their stable dose regimen
in both the treatment arm and the active control arm. TLANDO treatment was well tolerated in there were no hepatic, cardiac or
drug related SAEs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt">TLANDO safety highlights include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.15pt"></TD><TD STYLE="width: 10.85pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>TLANDO was well tolerated during 52 weeks of dosing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.15pt"></TD><TD STYLE="width: 10.85pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>Overall AE profile for TLANDO was comparable to the active control;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.15pt"></TD><TD STYLE="width: 10.85pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD STYLE="padding-right: 24pt">Cardiac AE profiles were consistent between treatment groups and none of the observed cardiac AEs
occurred in greater than 1.0% of the subjects in the TLANDO arm and none were classified as severe; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.15pt"></TD><TD STYLE="width: 10.85pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD STYLE="padding-right: 16pt">All observed adverse drug reactions (&ldquo;ADRs&rdquo;) were classified as mild or moderate in
severity and no serious ADRs occurred during the 52-week treatment period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Food Effect Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also completed our labeling
 &ldquo;food effect&rdquo; study in May 2015. Results from the labeling &ldquo;food effect&rdquo; study indicate that bioavailability
of testosterone from TLANDO is not affected by changes in meal fat content. The results demonstrate comparable testosterone levels
between the standard fat meal (similar to the meal instruction provided in the Phase 3 clinical study) and both the low and high
fat meals. The labeling &ldquo;food effect&rdquo; study was conducted per the FDA requirement and we submitted preliminary results
from this study to the FDA in the second quarter of 2015 prior to submitting the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Other Safety Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on our meetings with the
FDA, we do not expect to be required to conduct a heart attack and stroke risk study prior to the potential approval of TLANDO.
We may, however, be required to conduct a heart attack and stroke risk study on our own or with a consortium of sponsors that have
an approved TRT product subsequent to the potential approval of TLANDO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recent Competition Update</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 27, 2019, Clarus Therapeutics,
Inc.&rsquo;s (&ldquo;Clarus&rdquo;) product JATENZO&reg;, an oral testosterone undecanoate product, was approved by the FDA and
also received three years of data exclusivity. We don&rsquo;t know how Jatenzo&rsquo;s three years of data exclusivity will impact
the potential approvability of TLANDO, should the NDA be resubmitted. The Potential exists that the approval of TLANDO by the FDA
could be delayed until March 27, 2022. On February 10, 2020, Clarus announced that JATENZO&reg; has been launched and is commercially
available. Additionally on October 2, 2019, Clarus filed a Citizens Petition with the FDA requesting the FDA establish clear, written
guidance regarding the safety and efficacy standards required for oral testosterone drugs. The Citizens Petition also requested
that the FDA not approve any oral testosterone drugs until the written guidance is provided by the FDA. We will not know the impact
that Clarus&rsquo; Citizen Petition may have on TLANDO&rsquo;s approval, should the NDA be resubmitted, until the FDA addresses
the Citizens Petition specifically which may have an adverse effect on TLANDO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LPCN 1144: An Oral Prodrug of Bioidentical Testosterone Product
Candidate for the Treatment of NASH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are currently evaluating LPCN
1144, an oral prodrug of bioidentical testosterone comprised of TU, for the treatment of pre-cirrhotic NASH. NASH is a more advanced
state of non-alcoholic fatty liver disease (&ldquo;NAFLD&rdquo;) and can progress to a cirrhotic liver and eventually hepatocellular
carcinoma or liver cancer. Twenty to thirty percent of the U.S. population is estimated to suffer from NAFLD and fifteen to twenty
percent of this group progress to NASH, which is a substantially large population that lacks effective therapy. Currently, there
are no FDA approved treatments for NASH. Approximately 50% of NASH patients are in adult males and the number of NASH cases is
projected to increase 63% from 16.5 million cases in 2015 to 27.0 million cases in 2030. NAFLD/NASH is becoming more common due
to its strong correlation with obesity and metabolic syndrome, including components of metabolic syndrome such as diabetes, cardiovascular
disease and high blood pressure. In men, especially with comorbidities associated with NAFLD/NASH, testosterone deficiency has
been associated with an increased accumulation of visceral adipose tissue and insulin resistance, which could be factors contributing
to NAFLD/NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>History of Liver Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The liver is the largest internal
organ in the human body and its proper function is indispensable for many critical metabolic functions, including the regulation
of lipid and sugar metabolism, the production of important proteins, including those involved in blood clotting, and purification
of blood. There are over 100 described diseases of the liver, and because of its many functions, these can be highly debilitating
and life-threatening unless effectively treated. Liver diseases can result from injury to the liver caused by a variety of insults,
including hepatitis C virus (HCV), hepatitis B virus (HBV), obesity, chronic excessive alcohol use or autoimmune diseases. Regardless
of the underlying cause of the disease, there are important similarities in the disease progression including increased inflammatory
activity and excessive liver cell apoptosis, which if unresolved leads to fibrosis. Fibrosis, if allowed to progress, will lead
to cirrhosis, or excessive scarring of the liver, and eventually reduced liver function. Some patients with liver cirrhosis have
a partially functioning liver and may appear asymptomatic for long periods of time, which is referred to as decompensated liver
disease. Decompensated liver disease is when the liver is unable to perform its normal functions. Many people with active liver
disease remain undiagnosed largely because liver disease patients are often asymptomatic for many years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Markers of Liver Cell Death</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Alanine aminotransferase (&ldquo;ALT&rdquo;)
is an enzyme that is produced in liver cells and is naturally found in the blood of healthy individuals. In liver disease, liver
cells are damaged and as a consequence, ALT is released into the blood, increasing ALT levels above the normal range. Physicians
routinely test blood levels of ALT to monitor the health of a patient's liver. ALT level is a clinically important biochemical
marker of the severity of liver inflammation and ongoing liver disease. Elevated levels of ALT represent general markers of liver
cell death and inflammation without regard to any specific mechanism. Aspartate aminotransferase (&ldquo;AST&rdquo;) is a second
enzyme found in the blood that is produced in the liver and routinely measured by physicians along with ALT. As with ALT, AST is
often elevated in liver disease and, like ALT, is considered an overall marker of liver inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Relationship between Hypogonadism and NAFLD</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Preclinical and clinical studies
in the NAFLD/NASH literature have shown the prevalence of testosterone deficiency across the NAFLD/NASH histological spectrum wherein
low testosterone was independently associated with NAFLD/NASH with an inverse relationship between testosterone and NAFLD/NASH
symptom severity. A recent National Institute of Diabetes and Digestive and Kidney Diseases (&ldquo;NIDDK&rdquo;) report suggests
that 75% of biopsy confirmed NASH subjects have less than 372 ng/dL of total testosterone and that the degree of fibrosis severity
is inversely related to free testosterone levels; thus, providing a good rationale for testing LPCN 1144 in adult NASH patients
regardless of their hypogonadal status. Recently, we received clearance from the FDA to clinically investigate LPCN 1144 in an
expanded target population of adult male NASH patients. Specifically, the FDA waived the limitation of only testing LPCN 1144 in
NASH subjects with total testosterone levels below 300 ng/dL (threshold for hypogonadism).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Post hoc analyses of our existing
clinical trials in subjects with comorbidities typically associated with NASH comorbidities indicate that testosterone therapy
significantly and consistently reduced elevated levels of key serum biomarkers (liver function enzymes and serum triglyceride)
generally associated with NAFLD/NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Current Status</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have completed a 16-week POC liver imaging clinical study
to assess liver fat changes in hypogonadal men at risk of developing NASH using MRI-PDFF technique. Treatment results from the
POC liver imaging study demonstrated that 48% of the treated NAFLD subjects, defined as baseline liver fat of at least 5%, had
NAFLD resolution, defined as liver fat &lt;5% post treatment. Additionally, 100% of the subjects experiencing NAFLD resolution
had at least a 35% relative liver fat reduction from baseline with a relative mean liver fat reduction of 55% in this group. Further
results from the POC liver fat clinical study after 16 weeks of treatment are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
</FONT><FONT STYLE="font-size: 10pt">Baseline Liver Fat %</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Mean Liver Fat % at</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;Relative Reductions at EOS</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Responder Rate** at</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Category, n</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Baseline</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Mean %</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-left: 27pt"><FONT STYLE="font-size: 10pt">Median %</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">EOS, %</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; width: 20%"><FONT STYLE="font-size: 10pt">At least 10%, n=8</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 25%">20.5</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 7%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right; width: 1%"><FONT STYLE="font-size: 10pt">40</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt; width: 13%"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right; width: 27%"><FONT STYLE="font-size: 10pt">75</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">At least 8%, n=10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">18.3</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">42</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">42</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">80</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">At least 5%, n=21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">12.1</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">33</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">41</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">71</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">**Based on subjects who experienced at least a 30% reduction
in liver fat from baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, we have initiated the <I>LiFT</I>
(&ldquo;Liver Fat intervention with oral Testosterone&rdquo;) Phase 2 clinical study, a paired-biopsy study in confirmed pre-cirrhotic
NASH subjects with the first subject being dosed in the third quarter of 2019. The formulations being studied in the Phase 2 clinical
trial are differentiated from TLANDO. The <I>LiFT</I> Phase 2 clinical study is a prospective, multi-center, randomized, double-blind,
placebo-controlled multiple-arm study in biopsy-confirmed hypogonadal or eugonadal male NASH subjects with grade F2/F3 fibrosis
and a NAFLD Activity Score (&ldquo;NAS&rdquo;) &ge; 4 with a 36-week treatment period. The <I>LiFT</I> clinical study is designed
to enroll between 60 and 75 biopsy confirmed NASH male subjects, randomized into one of three arms (two test arms and one placebo
arm) with a 1:1:1 randomization ratio. We currently expect top-line liver fat reduction data in the second half of 2020, as measured
by MRI-PDFF at 12 weeks, followed by 36-week biopsy data which is expected by the first half of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TLANDO XR (LPCN 1111): A Next-Generation Lon-Acting Oral
Product Candidate for TRT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TLANDO XR (LPCN 1111) is a next-generation,
novel ester prodrug of testosterone which uses the Lip&rsquo;ral technology to enhance solubility and improve systemic absorption.
We completed a Phase 2b dose finding study in hypogonadal men in the third quarter of 2016. The primary objectives of the Phase
2b clinical study were to determine the starting Phase 3 dose of TLANDO XR (LPCN 1111) along with safety and tolerability of TLANDO
XR (LPCN 1111) and its metabolites following oral administration of single and multiple doses in hypogonadal men. The Phase 2b
clinical trial was a randomized, open label, two-period, multi-dose PK study that enrolled hypogonadal males into five treatment
groups. Each of the 12 subjects in a group received treatment for 14 days. Results of the Phase 2b study suggest that the primary
objectives were met, including identifying the dose expected to be tested in a Phase 3 study. Good dose-response relationship was
observed over the tested dose range in the Phase 2b study. Additionally, the target Phase 3 dose met primary and secondary end
points. Overall, TLANDO XR (LPCN 1111) was well tolerated with no drug-related severe or serious adverse events reported in the
Phase 2b study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally in October 2014, we completed
a Phase 2a proof-of-concept study in hypogonadal men. The Phase 2a open-label, dose-escalating single and multiple dose study enrolled
12 males. Results from the Phase 2a clinical study demonstrated the feasibility of a once daily dosing with TLANDO XR (LPCN 1111)
in hypogonadal men and a good dose response. Additionally, the study confirmed that steady state is achieved by day 14 with consistent
inter-day performance observed on day 14, 21 and 28. No subjects exceeded Cmax of 1500 ng/dL at any time during the 28-day dosing
period on multi-dose exposure. Overall, TLANDO XR (LPCN 1111) was well tolerated with no serious AE&rsquo;s reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have also completed a preclinical toxicology
study with LPCN 1111 in dogs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2018 we had a meeting with
the FDA to discuss these pre-clinical results and to discuss the Phase 3 clinical study and path forward for TLANDO XR (LPCN 1111).
Based on the results of the FDA meeting and additional pre-clinical trials conducted after the FDA meeting, we are designing a
Phase 3 protocol for TLANDO XR (LPCN 1111) and will solicit FDA feedback once the protocol is complete. Additionally, the FDA previously
requested that a food effect study be completed, and that ABPM be included as part of the Phase 3 clinical study. Based on our
capital resources and the clinical status of our product candidates, we plan to primarily focus our efforts in 2020 on LPCN 1144.
We do not anticipate the initiation of a Phase 3 study with LPCN 1111 to occur in 2020 unless and until additional capital is secured
or the product candidate is out-licensed. We are exploring the possibility of licensing LPCN 1111 to a third party, although no
licensing agreement has been entered into by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LPCN 1148: An Oral Prodrug of Bioidentical Testosterone Product
Candidate for the Treatment of NASH in Cirrhotic patients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NASH cirrhosis is an end stage NAFLD for
which there is no FDA approved drug treatment. During 2015, approximately 1.3 million NASH patients had cirrhosis (fibrosis grade
4). NASH cirrhosis patients typically experience increased morbidity and mortality and symptoms of hypogonadism such as alteration
of hair distribution, anemia, sexual dysfunction, testicular atrophy, muscle wasting, fatigue, osteoporosis, gynecomastia, etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Testosterone levels fall progressively
with increasing chronic liver disease severity. Low testosterone levels, reported in up to 90% of male cirrhotic patients, is known
to increase adverse outcomes and is a predictor of mortality in these patients with association with increased risk of major infections,
death and/ or transplantation rates, increased risk of for hepatic decompensation, worsening of sarcopenia, higher Child Pugh score
grade and Model for End-stage Liver Disease score as well as severity of portal hypertension and ascites grade.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are currently formulating plans to conduct
a proof-of-concept study in male cirrhotic NASH subjects through consultations with the FDA and key opinion leaders, and consistent
with recent FDA NASH cirrhosis guidance, to evaluate the therapeutic potential of LPCN 1148 for the treatment of cirrhotic NASH
subjects. We filed an Investigational New Drug application (&ldquo;IND&rdquo;) for LPCN 1148. Based on our capital resources and
the clinical status of our product candidates, we plan to primarily focus our efforts in 2020 on LPCN 1144. We do not anticapte
the initiation of a Phase 2 study with LPCN 1148 to occur in 2020 unless and until additional capital is secured or the product
candidate is out-licensed. We are exploring the possibility of licensing LPCN 1148 to a third party, although no licensing agreement
has been entered into by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0"><B>LPCN 1107: An Oral Product Candidate for the Prevention
of Preterm Birth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe LPCN 1107 has the potential
to become the first oral hydroxyprogesterone caproate (&ldquo;HPC&rdquo;) product indicated for the reduction of risk of preterm
birth (delivery less than 37 weeks) (&ldquo;PTB&rdquo;) in women with singleton pregnancy who have a history of singleton spontaneous
PTB. Prevention of PTB is a significant unmet need as approximately 11.7% of all U.S. pregnancies result in PTB, a leading cause
of neonatal mortality and morbidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have completed a multi-dose PK dose
selection study in pregnant women. The objective of the multi-dose PK selection study was to assess HPC blood levels in order to
identify the appropriate LPCN 1107 Phase 3 dose. The multi-dose PK dose selection study was an open-label, four-period, four-treatment,
randomized, single and multiple dose, PK study in pregnant women of three dose levels of LPCN 1107 and the injectable intramuscular
(&ldquo;IM&rdquo;) HPC (Makena&reg;). The study enrolled 12 healthy pregnant women (average age of 27 years) with a gestational
age of approximately 16 to 19 weeks. Subjects received three dose levels of LPCN 1107 (400 mg BID, 600 mg BID, or 800 mg BID) in
a randomized, crossover manner during the first three treatment periods and then received five weekly injections of HPC during
the fourth treatment period. During each of the LPCN 1107 treatment periods, subjects received a single dose of LPCN 1107 on Day
1 followed by twice daily administration from Day 2 to Day 8. Following completion of the three LPCN 1107 treatment periods and
a washout period, all subjects received five weekly injections of HPC. Results from this study demonstrated that average steady
state HPC levels (Cavg0-24) were comparable or higher for all three LPCN 1107 doses than for injectable HPC. Additionally, HPC
levels as a function of daily dose were linear for the three LPCN 1107 doses. Also, unlike the injectable HPC, steady state exposure
was achieved for all three LPCN 1107 doses within seven days. We have also completed a proof-of-concept Phase 1b clinical study
of LPCN 1107 in healthy pregnant women in January 2015 and a proof-of-concept Phase 1a clinical study of LPCN 1107 in healthy non-pregnant
women in May 2014. These studies were designed to determine the PK and bioavailability of LPCN 1107 relative to an IM HPC, as well
as safety and tolerability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A traditional pharmacokinetics/pharmacodynamics
(&ldquo;PK/PD&rdquo;) based Phase 2 clinical study in the intended patient population is not expected to be required prior to entering
into Phase 3. Therefore, based on the results of our multi-dose PK study we had an End-of-Phase 2 meeting and subsequent meetings
with the FDA to define a Phase 3 development plan for LPCN 1107. During the End-of-Phase 2 meeting and subsequent guidance meetings,
the FDA agreed to a randomized, open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator IM arm with treatment
up to 23 weeks. The FDA also provided preliminary feedback on other critical Phase 3 study design considerations including: positive
feedback on the proposed 800 mg BID Phase 3 dose and dosing regimen; confirmation of the use of a surrogate primary endpoint focusing
on rate of delivery less than 37 weeks gestation rather on clinical infant outcomes; acknowledgment that the use of a gestational
age endpoint would likely lead to any FDA approval, if granted, being a Subpart H approval; and, recommendation of a non-inferiority
study margin of 7% with interim analyses. A standard statistical design for a NI study based on the FDA feedback, a NI margin of
7% for the primary endpoint may require approximately 1,100 subjects per treatment arm with a 90% power. However, based on the
FDA&rsquo;s suggestion of including an interim analysis in the NI design, an adaptive study design is under consideration that
may allow for fewer subjects. We submitted the initial LPCN 1107 Phase 3 protocol to the FDA via a SPA in June 2017 and have received
multiple rounds of FDA feedback. Agreement with the FDA on the Phase 3 protocol via SPA has not occurred, as we were waiting for
the FDA&rsquo;s Advisory Committee meeting to occur for AMAG Pharmaceuticals&rsquo; Makena, which was held on October 29, 2019.
Additionally, a Phase 3 study will not occur until results from a planned food-effect study with LPCN 1107 are reviewed by the
FDA. Final agreement with the FDA on the Phase 3 protocol, if reached, may or may not confirm the FDA&rsquo;s preliminary feedback
on the Phase 3 design. Additionally, manufacturing scale-up work for LPCN 1107 has been completed. Based on our capital resources
and the clinical status of our product candidates, we plan to primarily focus our efforts in 2020 on LPCN 1144. We do not anticipate
the initiation of a Phase 3 study with LPCN 1107 to occur in 2020 unless and until additional capital is secured or the product
candidate is out-licensed. We are exploring the possibility of licensing LPCN 1107 to a third party, although no licensing agreement
has been entered into by the Company. No assurance can be given that any license agreement will be completed, or, if an agreement
is completed, that such an agreement would be on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

</div>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has granted
orphan drug designation to LPCN 1107 based on a major contribution to patient care. Orphan designation qualifies Lipocine for various
development incentives, including tax credits for qualified clinical testing, and a waiver of the prescription drug user fee when
we file our NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 8, 2019,
we received a Complete Response Letter from the FDA regarding our New Drug Application for TLANDO. The Complete Response letter
identified one deficiency stating the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations.
The CRL does not identify any specific issues relating to the chemistry, manufacturing and controls of TLANDO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">On
February 24, 2020, the Company announced the results of its post action meeting with the FDA regarding its NDA for TLANDO&trade;,
the Company's oral testosterone product candidate for TRT in adult males for conditions associated with a deficiency of endogenous
testosterone, also known as hypogonadism. Based on the Post Action meeting and written feedback, the FDA indicated the Company&rsquo;s
approach to addressing the single remaining deficiency through the reanalysis of existing data in accordance with FDA feedback
appears to be a reasonable path forward. The FDA requested that the information generated by the reanalysis be submitted as part
of an NDA resubmission with a six-month Prescription Drug User Fee Act clock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">On
November 14, 2019, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,&nbsp;</FONT><I>Solomon
Abady v. Lipocine Inc. et al.,&nbsp;</I><FONT STYLE="background-color: white">2:19-cv-00906-PMW, filed in the United District Court
for the District of Utah. The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose
that our filing of the NDA for TLANDO to the FDA contained deficiencies and as a result the defendants&rsquo; statements about
our business and operations were false and misleading and/or lacked a reasonable basis in violation of federal securities laws.
The lawsuit seeks certification as a class action (for a purported class of purchasers of the Company&rsquo;s securities from March
27, 2019 through November 8, 2019), compensatory damages in an unspecified amount, and unspecified equitable or injunctive relief.
We have insurance that covers claims of this nature. The retention amount payable by the Company under our policy is $2.5 million.
The Company intends to vigorously defend against this lawsuit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">As
of December 31, 2019, the Company had cash and cash equivalents of $19.1 million, $5.0 million of which is restricted cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marathon Bar Corp.
(&ldquo;Marathon Bar&rdquo;) was incorporated on October 13, 2011, in the State of Delaware. On July 24, 2013, Marathon Bar and
MBAR Acquisition Corp. (&ldquo;Merger Sub&rdquo;), a wholly owned subsidiary of Marathon Bar, and Lipocine Operating Inc. (&ldquo;Lipocine
Operating&rdquo;), a privately held company incorporated in Delaware, executed an Agreement and Plan of Merger (&ldquo;Merger Agreement&rdquo;).
Pursuant to the Merger Agreement, Merger Sub merged with and into Lipocine Operating and Lipocine Operating was the surviving entity.
Additionally, pursuant to the Merger Agreement, Marathon Bar changed its name to Lipocine Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 and our telephone number is
(801) 994-7383. We maintain a website at www.lipocine.com. Information contained in or accessible through our website does not
constitute a part of this prospectus supplement.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</div>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: center"><B><A NAME="a_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Class A Units offered by us in this offering</FONT></TD>
    <TD STYLE="width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering 10,084,034 Class A Units. Each Class&nbsp;A
Unit consists of one share of our common stock and one-half of one common stock purchase warrant to purchase shares of common stock.
The Class&nbsp;A Units will not be certificated and the shares of common stock and common stock purchase warrants comprising such
unit are immediately separable and will be issued separately in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement also relates to the offering of shares
of our common stock issuable upon the exercise of the common stock purchase warrants included in the Class&nbsp;A Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, see the section entitled &ldquo;Description
of Securities We Are Offering&rdquo; on page S-34 of this prospectus supplement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Offering price of Class A Units</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$0.595 per Class A Unit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Description of common stock purchase warrants </FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering common stock purchase warrants to purchase up
to 5,042,017&nbsp;shares of common stock, which may be exercised beginning on the date of issuance. The common stock purchase warrants
are exercisable until the five-year anniversary of the original issuance date. The common stock purchase warrants have an exercise
price of $0.53&nbsp;per share of common stock, subject to adjustment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common stock outstanding before this offering</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">37,649,465 shares.</P>



        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common stock outstanding immediately after this offering (assuming no exercise of warrants)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">47,733,499 shares.</P>



        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</div>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding: 0in 3pt; overflow: visible; width: 99%">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="width: 70%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate that our net proceeds from this offering, after
deducting placement agent commissions and estimated offering expenses payable by us, will be approximately $5.6 million. We currently
intend to use the net proceeds from this offering for general corporate purposes. See &ldquo;Use of Proceeds&rdquo; on page S-31
of this prospectus supplement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Best Efforts</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent has agreed to use its reasonable best efforts
        to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities
        from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required
        minimum number of securities that must be sold as a condition to completion of this offering. See &ldquo;Plan of Distribution&rdquo;
        on page S-37 of this prospectus supplement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our securities involves a high degree of risk.
        You should consider carefully all of the information included or incorporated by reference in this prospectus supplement and the
        sections entitled &ldquo;Risk Factors&rdquo; beginning on page S-15 of this prospectus supplement, page 5 of the accompanying prospectus,
        page 19 of our Annual Report on Form 10-K for the year ended December 31, 2018, page 33 of our Quarterly Report on Form 10-Q for
        the three months ended March 31, 2019, page 34 of our Quarterly Report on Form 10-Q for the six months ended June 30, 2019, page
        36 of our Quarterly Report on Form 10-Q for the nine months ended September 30, 2019 and under similar headings in the other documents
        that are filed after the date hereof and incorporated by reference in this prospectus supplement before deciding whether to purchase
        our common stock in this offering.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Market for common stock</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on Nasdaq under the symbol &ldquo;LPCN.&rdquo;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Market for warrants</FONT></TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">There is no established public trading market for the common
stock purchase warrants, and we do not expect a trading market to develop. In addition, we do not intend to apply for listing of
the common stock purchase warrants on any securities exchange or recognized trading system.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of shares
of common stock to be outstanding after this offering as reflected in the table above is based on the actual number of shares outstanding
as of December 31, 2019, which was 37,649,465 shares, which does not include, as of that date, (i) 2,310,485 options to purchase
shares of our common stock issued under our Third Amended and Restated 2014 Stock and Incentive Plan and our 2011 Equity Incentive
Plan, (ii) 661,307 restricted stock units of our common stock issued under our Third Amended and Restated 2014 Stock and Incentive
Plan and (iii) 12,000,000 shares of common stock underlying outstanding warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
</div>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Before you make a decision to invest
in our securities, you should consider carefully the risks described below, together with other information in this prospectus
supplement, the accompanying prospectus and the information incorporated by reference herein and therein, including any risk factors
contained in our annual and other reports filed with the SEC. If any of the following events actually occur, our business, operating
results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our
common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we
face. Additional risks not presently known to us or that we currently deem immaterial may also significantly impair our business
operations and could result in a complete loss of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RISKS RELATED TO THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Since we have broad discretion in
how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not allocated specific amounts of
the net proceeds from this offering for any specific purpose. Accordingly, our management will have some flexibility in applying
the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds,
and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure
of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating
results and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate dilution
in the book value per share of the common stock you purchase.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because the price per share of our common
stock being offered is substantially higher than the book value per share of our common stock, you will suffer substantial dilution
in the net tangible book value of the common stock you purchase in this offering. After giving effect to the sale by us of shares
of common stock in this offering, and based on a public offering price of $0.595&nbsp;per Class A Unit and a pro forma net tangible
book value per share of our common stock of $0.30 as of September 30, 2019, if you purchase securities in this offering, you will
suffer immediate and substantial dilution of $0.221 per share in the net tangible book value of the common stock purchased. The
exercise of outstanding stock options and the vesting of outstanding restricted stock units will result in further dilution of
your investment. See &ldquo;Dilution&rdquo; on page S-32 for a more detailed discussion of the dilution you will incur in connection
with this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience future dilution
as a result of future equity offerings. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to raise additional capital, we
may at any time, including during the pendency of this offering, offer additional shares of our common stock or other securities
convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering.
We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by
investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable
into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>This offering is being conducted on a &ldquo;best efforts&rdquo;
basis.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The placement agent has agreed to use its
reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to
buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities.
There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there
is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent
fees and proceeds to us are not presently determinable. Thus, we may not raise the amount of capital we believe is required for
our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The warrants are speculative in nature.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of the warrants offered hereby confer
any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely
represent the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date of issuance of the
warrants, holders of the common stock purchase warrants may acquire the common stock issuable upon exercise of such common stock
purchase warrants at an exercise price of $0.53&nbsp;per share. The common stock purchase warrants will expire on the&nbsp;fifth
anniversary of the date they first become exercisable. There can be no assurance that it will ever be profitable for holders of
the warrants to exercise the common stock purchase warrants.<B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Significant holders or beneficial
holders of our common stock may not be permitted to exercise warrants that they hold.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The warrants being offered hereby will prohibit
a holder from exercising its warrants if doing so would result in such holder (together with such holder&rsquo;s affiliates and
any other persons acting as a group together with such holder or any of such holder&rsquo;s affiliates) beneficially owning more
than 4.99% of our common stock outstanding immediately after giving effect to the exercise, provided that, at the election of a
holder and notice to us, such beneficial ownership limitation shall be 9.99% of our common stock outstanding immediately after
giving effect to the exercise. As a result, if you hold a significant amount of our securities, you may not be able to exercise
your warrants for shares of our common stock, in whole or in part, at a time when it would be financially beneficial for you to
do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the
warrants in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is no established public trading market
for the warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply
to list the warrants on any securities exchange. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of the warrants will have
no rights as a common stockholder until they acquire our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until you acquire shares of our common stock
upon exercise of your warrants, you will have no rights with respect to shares of our common stock issuable upon exercise of your
warrants. Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as to matters
for which the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RISKS RELATING TO OUR BUSINESS AND INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend primarily on the success
of our lead product candidate, TLANDO, for which we recently received a Complete Response Letter from the FDA and which may not
receive regulatory approval or be successfully commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">TLANDO
is currently our only product candidate that has completed Phase 3 clinical trials, and our business currently depends primarily
on its successful development, regulatory approval and commercialization, if approved. On November 8, 2019 we received a CRL from
the FDA regarding our NDA filed in May 2019 for TLANDO as a TRT in adult males for conditions associated with a deficiency of endogenous
testosterone, also known as hypogonadism</FONT>. <FONT STYLE="font-size: 10pt">The CRL identified one deficiency stating the efficacy
trial did not meet the three secondary endpoints for maximal testosterone concentrations (&ldquo;Cmax&rdquo;). The CRL did not
identify any specific issues relating to chemistry, manufacturing and controls (&ldquo;CMC&rdquo;) of TLANDO. Previously, we have
received two other CRL&rsquo;s from the FDA on TLANDO NDA submissions. The first CRL was received on June 28, 2016 and the second
CRL was received on May 8, 2018. We have not submitted comparable applications to other regulatory authorities. If the FDA denies
or further delays approval of TLANDO, our business would be materially and adversely harmed. If the FDA does approve TLANDO, but
we are unsuccessful in commercializing TLANDO, our business will be materially and adversely harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As we have received
another CRL from the FDA, approval of TLANDO will be substantially delayed and additional studies and expense may be required before
we would be in a position to resubmit an NDA to address the CRL deficiencies. Our ability to raise capital may also be impaired.
If we proceed with any study, we face the risk that the FDA would not agree with the design or results of the study.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The FDA may also ask
us to perform additional clinical trials or studies, either pre- or post- approval, or provide additional information in order
to secure approval. Any such requirement would increase our costs and delay approval and commercialization of TLANDO and would
have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Even if TLANDO is approved,
the FDA may limit the indications for which it may be used, include extensive warnings on the product labeling, or require costly
ongoing requirements for post-marketing clinical studies including participation in a long-term TRT consortium cardiovascular study
and surveillance or other risk management measures to monitor the safety or efficacy of TLANDO. Further, in the event that we seek
regulatory approval of TLANDO outside the United States, such markets also have requirements for approval of drug candidates with
which we must comply prior to marketing. Obtaining regulatory approval for marketing of TLANDO in one country does not ensure we
will be able to obtain regulatory approval in other countries but a failure or delay in obtaining regulatory approval in one country
may have a negative effect on the regulatory process in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any regulatory approval
of TLANDO, once obtained, may be withdrawn. Ultimately, the failure to obtain and maintain regulatory approvals would prevent TLANDO
from being marketed and would have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If the FDA clarifies, modifies or restricts the indicated
population for T-replacement in the &quot;class&quot; label, the market for T-replacement products may shrink and our ability to
sell and be reimbursed for TLANDO and TLANDO XR (LPCN 1111) could be materially adversely affected and our business could be harmed.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 17, 2014, the FDA held a T-class
Advisory Committee meeting. The Advisory Committee discussed (i) the identification of the appropriate patient population for whom
T-replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined as non-fatal
stroke, non-fatal myocardial infarction and cardiovascular death associated with T-replacement therapy. At the meeting, 20 of the
21 members of the Advisory Committee voted that the FDA should revise the currently indicated population for T-replacement therapy
and recommended changing the label language to restrict the intended uses of the products, particularly in relation to age-related
low testosterone. The Committee also supported adding language to the label to guide physicians in better diagnosis of eligible
patients for treatment. On March 3, 2015, the FDA issued a safety announcement addressing the Advisory Committee&rsquo;s recommendations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA's safety assessment recommended
the following label modifications/restrictions in the indicated population for T-replacement therapy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limiting use of T-replacement products to men who have low testosterone caused by certain medical conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prior to initiating use of T-replacement products, confirm diagnosis of hypogonadism by ensuring that serum testosterone has
been measured in the morning on at least two separate days and that these concentrations are below the normal range;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>adding cautionary language stating that the safety and efficacy of TRT products with age-related hypogonadism have not been
established; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>adding cautionary language stating that some studies have shown an increased risk of myocardial infarction and stroke associated
with use of T-replacement products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The actual TRT label revisions have been
finalized between the FDA and sponsors with approved T-replacement therapy products. The revised labels are consistent with the
FDA's recommendations on March 3, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, the FDA stated that they will
require manufacturers of approved T-replacement products to conduct a well-designed clinical trial to more clearly address the
question of whether an increased risk of heart attack or stroke exists among users of T-replacement products. The FDA encouraged
manufacturers to work together on conducting a clinical trial, although the FDA will allow manufacturers to work separately if
they so choose. The FDA did not address whether it would require sponsors without an approved T-replacement product to conduct
a cardiovascular trial prior to being able to file an NDA. However, on March 19, 2015 we had a pre-NDA meeting with the FDA concerning
our pivotal Phase 3 trial for TLANDO. Based on this meeting with the FDA, we do not expect to be required to conduct a heart attack
and stroke risk study or any additional safety studies prior to approval of the NDA for TLANDO. More recently the FDA has determined
that an ABPM study is required to better assess any blood pressure effects of TLANDO, a surrogate marker of predicting cardiovascular
outcome. The ABPM clinical study was completed in the first quarter of 2019. If the FDA changes its position, however, and concludes
that a cardiovascular trial is required prior to approving our NDA for TLANDO, such trial would require substantial financial resources,
and would delay the regulatory process for TLANDO and our entry into the marketplace, all of which would have a material adverse
impact on our business. Further, if TLANDO receives FDA approval, it is unclear what our post-approval obligations may be, if any,
in relation to a heart attack and stroke risk study. We may be required to contribute to an on-going industry-led heart attack
and stroke risk study or to conduct our own long-term heart attack and stroke risk study, either of which would require substantial
financial resources and would have a material adverse impact on our business. If the market for T-replacement products declines,
for whatever reason, our business will be materially and adversely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If T-replacement therapies are found, or are perceived,
to create health risks, our ability to sell TLANDO and TLANDO XR (LPCN 1111) could be materially adversely affected and our business
could be harmed. Even if our TLANDO and our TLANDO XR (LPCN 1111) are approved, physicians and patients may be deterred from prescribing
and using T-replacement therapies, which could depress demand for TLANDO and TLANDO XR (LPCN 1111) and compromise our ability to
successfully commercialize TLANDO and TLANDO XR (LPCN 1111). </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain publications have suggested potential
health risks associated with T-replacement therapy, such as increased cardiovascular disease risk, including increased risk of
heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood cells, development
of clinical prostate disease, including prostate cancer, and the suppression of sperm production. These potential health risks
are described in various articles, including the following publications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a 2014 publication in PLOS ONE, which found that, compared to the one year prior to beginning T-replacement therapy, the risk
of heart attack doubled 90 days after the start of T deficiency treatment in older men regardless of their history of heart disease
and was two to three times higher in men younger than 65 with a history of heart disease;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a 2013 publication in the <I>Journal of the American Medical Association</I>, which reported that hypogonadal men receiving
T-replacement therapy developed a 30% increase in the risk of stroke, heart attack and death; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a 2013 publication in BMC Medicine, which concluded that exogenous T increased the risk of cardiovascular-related events, particularly
in trials not funded by the pharmaceutical industry.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prompted by these events, the FDA announced
on January 31, 2014 that it will investigate the risk of stroke, heart attack, and death in men taking FDA-approved testosterone
products and that the FDA would hold a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further.
The FDA has also asked health care professionals and patients to report side effects involving prescription testosterone products
to the agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the FDA's announcement, the Endocrine
Society, a professional medical organization, released a statement in February 2014 in support of further studies regarding the
risks and benefits of FDA-approved T-replacement products for men with age-related T deficiency. Specifically, the Endocrine Society
noted that large-scale randomized controlled trials are needed to determine the risks and benefits of T-replacement therapy in
older men. In addition, the Endocrine Society recommended that patients should be informed of the potential cardiovascular risks
in middle-aged and older men associated with T-replacement therapies. Also following the FDA's announcement, Public Citizen, a
consumer advocacy organization, petitioned the FDA to add a &quot;black box&quot; warning about the increased risks of heart attacks
and other cardiovascular dangers to the product labels of all T-replacement therapies. In addition, this petition urged the FDA
to delay its decision date on approving Aveed, a long-acting T-injectable developed by Endo, which was subsequently approved by
the FDA in March 2014. In July 2014, the FDA responded to the Public Citizen petition and denied the petition. Additionally, in
June 2014 the FDA announced that it would require the manufacturers of testosterone drugs to update the warning label to include
blood clots including deep vein thrombosis (&quot;DVT&quot;) and pulmonary embolism (&quot;PE&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the T-class Advisory Committee meeting
held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population for whom
T-replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined as non-fatal
stroke, non-fatal myocardial infarction and cardiovascular death associated with T-replacement therapy. At the meeting, 16 of the
21 members of the Advisory Committee voted that the FDA should require sponsors of testosterone products to conduct a post marketing
study (e.g. observational study or controlled clinical trial) to further assess the potential cardiovascular risk. Further, 12
of these voted that such post marketing study be required only if the T-replacement therapy is also approved for age-related hypogonadism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Advisory Committee also held a meeting
on September 18, 2014 to evaluate the safety and efficacy of Jatenzo (previously Rextoro), an oral TU submitted to the FDA by Clarus
Therapeutics for the proposed indication of T-replacement therapy. 18 of the 21 members of the Advisory Committee voted that the
overall benefit/risk profile of Jatenzo was not acceptable to support approval for T-replacement therapy. The Advisory Committee
agreed that an oral TU as a T-replacement therapy is promising and that it would be of great value to patients to have an oral
treatment option, but they did not believe the current Jatenzo data supported approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 3, 2015, the FDA issued a safety
announcement addressing the Advisory Committee&rsquo;s recommendations and communicated its expectations related to label revisions
and additional clinical requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA's safety assessment recommended
the following label modifications/restrictions in the indicated population for T-replacement therapy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limiting use of T-replacement products to men who have low testosterone caused by certain medical conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prior to initiating use of T-replacement products, confirm diagnosis of hypogonadism by ensuring that serum testosterone has
been measured in the morning on at least two separate days and that these concentrations are below the normal range;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>adding cautionary language stating that the safety and efficacy of TRT products with age-related hypogonadism have not been
established; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>adding cautionary language stating that some studies have shown an increased risk of myocardial infarction and stroke associated
with use of T-replacement products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, the FDA stated that they will
require manufacturers of approved T-replacement products to conduct a well-designed clinical trial to more clearly address the
question of whether an increased risk of heart attack or stroke exists among users of T-replacement products. The FDA encouraged
manufacturers to work together on conducting a clinical trial, although the FDA will allow manufacturers to work separately if
they so choose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 9, 2018, a BRUDAC meeting was
held for Jatenzo, Clarus Therapeutics&rsquo; testosterone replacement therapy product candidate. The BRUDAC voted nine in favor
and ten against the acceptability of the overall benefit/risk profile to support approval of Jatenzo as a TRT. Jatenzo, a competing
oral TU TRT product candidate to TLANDO, has shown a clinically meaningful increase in blood pressure. The FDA may consider this
blood pressure increase by a product with the same active ingredient as TLANDO to be an oral TU class effect. Therefore, irrespective
of our TLANDO ABPM study findings we may not be successful in overcoming the FDA&rsquo;s belief that the increase in blood pressure
is an oral TU class effect rather than a product candidate specific effect. This may result in a TLANDO non- approval, increased
label warnings or agreeing to REMS and/or post approval label comprehension study as a condition for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, the FDA convened a BRUDAC
meeting on January 10, 2018 to evaluate the safety and efficacy of TLANDO as a T-replacement product. The BRUDAC voted six in favor
and thirteen against the acceptability of the overall benefit/risk profile to support approval of TLANDO as a TRT and ultimately
a CRL was received from the FDA citing four deficiencies on May 8, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also, on September 29, 2018, Antares Pharma,
Inc. announced that it had received approval from the FDA regarding its NDA for XYOSTED&trade; (testosterone enanthate) injection.
However, based on clinical results XYOSTED&rsquo;s label is required to contain a black box warning concerning blood pressure increases.
Additionally, the FDA also required the following specific language to be included in XYOSTED&rsquo;s label, &ldquo;In some patients
the increase in blood pressure with XYOSTED may be too small to detect, but can still increase the risk of major adverse cardiovascular
events (&ldquo;MACE&rdquo;)&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally on February 4, 2019, the FDA
held a public workshop entitled, &ldquo;Evaluating the Pressor Effects of Drugs &amp; Ambulatory Blood Pressure Monitoring Studies&rdquo;.
The purpose of the workshop was to bring together the stakeholder community, including company sponsors, FDA, and key opinion leaders,
to discuss the premarketing assessment of a drug&rsquo;s effect on blood pressure. Topics discussed by the FDA included: study
design considerations to definitively assess a drug&rsquo;s effect on blood pressure and appropriate regulatory action; the need
to raise physician and patient awareness via labeling or risk mitigation strategies based on blood pressure effects and associated
increased cardiovascular risks; the assessment of clinical meaningfulness of blood pressure changes based on findings; appropriately
identifying the population at risk; and, a drug&rsquo;s benefit risk analyses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is possible that the FDA's evaluation
of this topic and further studies on the effects of T-replacement therapies could demonstrate the risk of major adverse cardiovascular
events or other health risks or could impose additional requirements that could delay our approval for TLANDO. During our SOAR
trial, we collected safety data for TLANDO and a control group, the leading approved T-gel product, but we did not compare safety
data from TLANDO to a placebo control group or the control group. If, following its evaluation, the FDA concludes that men using
FDA-approved T-replacement therapies face serious cardiovascular risks, it may take actions against T-replacement products generally,
which could impact us adversely in a variety of ways, including that the FDA could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require additional safety studies before approving TLANDO;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>mandate that certain warnings or precautions be included in our product labeling;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require that our product carry a &quot;black box warning&quot;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit use of TLANDO and TLANDO XR (LPCN 1111) to certain populations, such as men without specified conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>direct us to submit a Risk Evaluation and Mitigation Strategy (&quot;REMS&quot;) as part of our NDA to help ensure that the
benefits of our product outweigh the potential risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require that we conduct post-marketing studies, potentially including registry, epidemiology or cardiovascular outcomes studies;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit the prospects for regulatory approval and commercial success of our TLANDO and TLANDO XR (LPCN 1111).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Demonstrated T-replacement therapy safety
risks, as well as negative publicity about the risks of hormone replacement therapy, including T-replacement, could hurt sales
of and impair our ability to successfully commercialize TLANDO and TLANDO XR (LPCN 1111), if approved. If the FDA changes its position
from only requiring an ABPM study, however, and concludes that a cardiovascular trial is required prior to approving our NDA for
TLANDO, such trial would require substantial financial resources, would delay the regulatory process for TLANDO and our entry into
the marketplace, all of which would have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face substantial competition in the TRT market, which
may result in others discovering, developing or commercializing products before or more successfully than we do.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to face significant competition
for any of our product candidates, if approved. In particular, if approved, TLANDO would compete in the T-replacement therapies
market, which is highly competitive and currently dominated by the sale of T-gels in terms of sales dollars and T-injectables in
terms of prescriptions. Our success will depend, in large part, on our ability to obtain an adequate share of the market. Potential
competitors in North America, Europe and elsewhere include major pharmaceutical companies, specialty pharmaceutical companies,
biotechnology firms, universities and other research institutions and government agencies. Other pharmaceutical companies may develop
oral T-replacement therapies that compete with TLANDO. For example, because TU is not a patented compound and is commercially available
to third parties, it is possible that competitors may design methods of TU administration that would be outside the scope of the
claims of either our issued patents or our patent applications. This would enable their products to effectively compete with TLANDO,
which could have a negative effect on our business<B><I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following T-replacement therapies currently
on the market in the United States would compete with TLANDO:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Oral-T, such as Jatenzo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>T-gels, such as AndroGel (marketed by Abbvie) and Perrigo's AB-rated 1% generic of AndroGel, Teva&rsquo;s 1% generic of AndroGel,
Testim (marketed by Endo Health Solutions, or Endo), and Fortesta (marketed by Endo);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>T-topical solutions, such as Axiron, a metered dose lotion marketed by Eli Lilly and Co. and related authorized generics;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>T-injectables, including a subcutaneous auto-injector, XYOSTED, marketed by Antares Pharma, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Branded longer-acting injectables, such as Aveed (marketed by Endo);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>T-nasals, such as Natesto (marketed by Aytu);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>methyl-T, such as Methitest (marketed by Impax) and Testred (marketed by Valeant);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>transdermal patches, such as Androderm (marketed by Allergan.);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>buccal patches, such as Striant (marketed by Endo);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>generic testosterone enanthate intra-muscular injectables;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorized generic and generic T-gels; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>subcutaneous injectable pellets, such as Testopel (marketed by Endo).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are also aware of other pharmaceutical
companies that have T-replacement therapies or testosterone therapies in development that may be approved for marketing in the
United States or outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on publicly available information,
we believe that several other T-replacement therapies that would be competitive with TLANDO are in varying stages of development,
some of which may be approved, marketed and/or commercialized prior to TLANDO. These therapies include T-gels, oral-T, an aromatase
inhibitor, a new class of drugs called Selective Androgen Receptor Modulators and hydroalcoholic gel formulations of DHT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In light of the competitive landscape above,
TLANDO will not be the only oral testosterone replacement therapy to market, which may significantly affect the market acceptance
and commercial success of TLANDO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, many of our potential competitors
have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery
and development of drug candidates, obtaining FDA and other marketing approvals of products and the commercialization of those
products. These competitors have the economic power to acquire and maintain market share, limiting our ability to penetrate the
TRT market with our TLANDO product. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval
for drugs and achieving widespread market acceptance. Our competitors&rsquo; drugs may be more effective, or more effectively marketed
and sold, than our products and may render our products obsolete or non-competitive before we can recover the expenses of developing
and commercializing them. We anticipate that we will face intense and increasing competition as new drugs enter the market and
advanced technologies become available. Failure to successfully compete in this market would materially and negatively impact our
business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The entrance of generic T-gels into the market would likely
create downward pricing pressure on all T-replacement therapies and therefore have a negative effect on our business and financial
results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several companies have filed Abbreviated
New Drug Applications, or ANDAs, seeking approval for generic versions of existing T-gels. For example, in April 2012 Perrigo Company
filed an ANDA with the FDA seeking approval for a generic version of AndroGel 1.62%. In response to this ANDA, the marketer of
AndroGel 1.62% filed patent infringement lawsuits against Perrigo Company to block the approval and marketing of the generic product.
In August 2015, the FDA approved the ANDA submitted by Perrigo Company and Perrigo&rsquo;s generic product was also granted 180
days of generic drug exclusivity. The marketer of AndroGel 1.62% may enter into an agreement with Perrigo Company to delay the
introduction of a generic AndroGel 1.62%. Additionally, in July 2003, Actavis and Par Pharmaceutical, or Par, filed ANDAs with
the FDA seeking approval for generic versions of AndroGel 1%. In response to these ANDAs, the marketer of AndroGel 1% filed patent
infringement lawsuits against these two companies to block the approval and marketing of the generic products. In 2006, all the
subject companies reached an agreement pursuant to which Actavis agreed not to bring a generic version of AndroGel 1% to the market
until August 2015, and Par agreed not to bring a generic version to market until February 2016. The U.S. Federal Trade Commission
has questioned the legality of such &ldquo;pay-to-delay&rdquo; agreements, and the Supreme Court ruled in June 2013 that such agreements
may not be valid. The impact of this ruling on the agreements between the marketer of AndroGel 1% and Actavis and Par, as well
as the timing and eventual marketing of generic versions of their respective products, is uncertain at this point.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, there are several other ANDAs
for generic T-gels that have been filed and there is ongoing litigation with each of these ANDAs. Finally, in 2014, two authorized
generic T-gels were launched at a lower price than the branded version of the same T-gel. With generic version of T-gel becoming
available in the market, governmental and other pressures to reduce pharmaceutical costs have resulted in physicians writing prescriptions
for generic T-gels as opposed to branded T-gels. The entrance of these generic T-gel into the market has caused downward pressure
on the pricing of all T-replacement therapies and has materially and adversely affected the level of sales and price at which we
could sell TLANDO, and ultimately materially and adversely impact our revenues and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The introduction of generic T-gel, may also
affect the reimbursement policies of government authorities and third-party payors, such as private health insurers and health
maintenance organizations. These organizations determine which medications they will pay for and establish reimbursement levels.
Cost containment is a primary concern in the U.S. healthcare industry and elsewhere. Government authorities and these third-party
payers have attempted to control costs by limiting coverage and the amount of reimbursement for branded medications when there
is a generic available. With generic T-gels available in the market, that creates an additional obstacle to the availability of
reimbursement for TLANDO. Even if reimbursement is available, the level of such reimbursement could be reduced or limited. Reimbursement
may impact the demand for, or the price of, TLANDO. If reimbursement is not available or is available only at limited levels, we
may not be able to successfully commercialize TLANDO, and/or our financial results from the sale of related products could be negatively
and materially impacted. Rebates and other pricing strategies of generics may erode our revenue and harm our financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, TLANDO will not be the first
oral testosterone replacement therapy product to market. If the generic version of a competing oral testosterone replacement therapy
product enters the market before TLANDO, then the commercial prospects of TLANDO could be materially and negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>LPCN 1144 is in a very early stage of development and
may not be further developed for a variety of reasons. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">LPCN 1144 is in a very early stage of development
and consequently the risk that we fail to commercialize LPCN 1144 and related products is high. In particular, we have only recently
completed a POC liver imaging clinical study. Treatment results from our POC liver imaging clinical study demonstrated that 48%
of the treated NAFLD subjects had NAFLD resolution, defined as liver fat &lt;5% post treatment. Additionally, the POC liver imaging
clinical study showed a relative mean reduction from baseline of 40% liver fat in subjects with baseline liver fat &gt; 10%. Moreover,
there was a 75% responder rate in which subjects experienced at least a 30% relative reduction in liver fat from baseline. Although
our POC liver imaging clinical study results were positive, these results from a small single-arm clinical study may not be indicative
of ultimate success in a larger Phase 2/3, such as the Phases 2 <I>LiFT</I> clinical study, with required FDA end-points and populations
needed for regulatory approval of LPCN 1144 for the treatment of NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, a number of companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials, even after achieving
positive results in early stage development. Accordingly, our results from our POC study may not be predictive of the results we
may obtain from further studies and trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Several factors
could significantly affect the prospects for LPCN 1144, including factors relating to the regulatory approval, competitive landscape
and clinical development challenges for LPCN 1144. The anticipated Phase 2 and Phase 3 programs for an NDA filing for LPCN 1144
will be very long and resource intensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>LPCN 1107 is in a very early stage of development and
may not be further developed for a variety of reasons. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">LPCN 1107 is in a very early stage of development
and consequently the risk that we fail to commercialize LPCN 1107 and related products is high. In particular, we have only conducted
three Phase 1 clinical studies with this product candidate. Two of the studies were in healthy pregnant women and one was in healthy
women. Although these studies demonstrated oral absorption of LPCN 1107 is possible, we may not be able to match or exceed Cavg
blood levels shown with the intramuscular injection comparator product over a longer duration. Furthermore, our completed Phase
1 clinical studies may not be predictive of safety concerns that may arise in pregnant women or demonstrate that LPCN 1107 has
an adequate safety profile to warrant further development. The FDA may also require further preclinical studies. All of these factors
can impact the timing of and our ability to continue development of LPCN 1107.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, a number of companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials, even after achieving
positive results in early stage development. Accordingly, our results from our Phase 1a, our Phase 1b and our multi-dose PK dose
selection studies may not be predictive of the results we may obtain from further studies and trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A traditional pharmacokinetics/pharmacodynamics
(&ldquo;PK/PD&rdquo;) based Phase 2 clinical study in the intended patient population may not be required prior to entering into
Phase 3. Therefore, based on the results of our multi-dose PK study results, we had an End-of-Phase 2 meeting with the FDA in the
second quarter of 2016, as well as subsequent guidance meetings to agree on a Phase 3 development plan for LPCN 1107. During the
End-of-Phase 2 meeting and subsequent guidance meetings, the FDA agreed to a randomized, open-label, two-arm clinical study to
include a LPCN 1107 arm and a comparator IM arm with treatment up to 23 weeks. The FDA also provided feedback on other critical
Phase 3 study design considerations including: positive feedback on the proposed 800 mg BID Phase 3 dose and dosing regimen; confirmation
of the use of a surrogate primary endpoint focusing on rate of delivery less than 37 weeks gestation rather on clinical infant
outcomes; acknowledged that the use of a gestational age endpoint would likely lead to FDA approval, if granted, being a Subpart
H approval as opposed to a full approval; and, recommended a non-inferiority study margin of 7% with interim analyses. A standard
statistical design for a NI study based on the FDA suggested NI margin of 7% for the primary end point may require ~1,100 subjects
per treatment arm with a 90% power. However, based on the FDA&rsquo;s feedback of including an interim analysis in the NI design,
an adaptive study design is under consideration that may allow for fewer subjects. We submitted the initial LPCN 1107 Phase 3 protocol
to the FDA via a SPA in June 2017 and have received multiple rounds of FDA feedback. Agreement with the FDA on the Phase 3 protocol
via SPA has not occurred and will not occur until results from a planned food-effect study with LPCN 1107 are reviewed by the FDA.
Agreement with the FDA on the Phase 3 protocol via SPA has not occurred as we were waiting for minutes from the FDA&rsquo;s Advisory
Committee meeting for AMAG Pharmaceuticals&rsquo; Makena which was held on October 29, 2019. Final agreement with the FDA on the
Phase 3 protocol, if reached, may or may not confirm the FDA&rsquo;s preliminary feedback on the Phase 3 design. Additionally,
manufacturing scale-up work for LPCN 1107 has been complete. Once the Phase 3 clinical trial is started, the anticipated Phase
3 program for an NDA filing for LPCN 1107 will be very long and expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Due to our reliance on CROs or other third parties to
assist us or have historically assisted us in conducting clinical trials, we will be unable to directly control all aspects of
our clinical trials</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We engaged a CRO to conduct our SOAR, DV
and DF Phase 3 clinical studies for TLANDO as well as the ABPM study for TLANDO and the liver imaging study for LPCN 1144. Additionally,
we are utilizing a CRO for the on-going Phase 2 <I>LiFT</I> clinical study for LPCN 1144. As a result, we have less direct control
over the conduct of our clinical trials, the timing and completion of the trials and the management of data developed through the
trials than if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially
leading to mistakes as well as difficulties in coordinating activities. Outside parties, including CROs, may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>have staffing difficulties or disruptions;</TD></TR>                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>fail to comply with contractual obligations;</TD></TR>                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>experience regulatory compliance issues;</TD></TR>                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>undergo changes in priorities or may become financially distressed;</TD></TR>                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>form relationships with other entities, some of which may be our competitors; or</TD></TR>                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>manufacturing capacity limitations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These factors may materially adversely affect
their willingness or ability to conduct our trials in a manner acceptable to us. We may experience unexpected cost increases that
are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, the FDA requires us to comply
with standards, commonly referred to as Good Clinical Practices, or GCP, for conducting, recording, and reporting the results of
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities
and requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Problems with the timeliness or quality
of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making
this change may be costly and may delay our trials, and contractual restrictions may make such a change difficult or impossible.
If we must replace any CRO that is conducting our clinical trials, our trials may have to be suspended until we find another CRO
that offers comparable services. The time that it takes us to find alternative organizations may cause a delay in the commercialization
of our product candidates or may cause us to incur significant expenses to replicate data that may be lost. Although we do not
believe that any CRO on which we may rely will offer services that are not available elsewhere, it may be difficult to find a replacement
organization that can conduct our trials in an acceptable manner and at an acceptable cost. Any delay in or inability to complete
our clinical trials could significantly compromise our ability to secure regulatory approval of our product candidates and preclude
our ability to commercialize them, thereby limiting or preventing our ability to generate revenue from their sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TLANDO XR (LPCN 1111) is in a very early stage of development
and may not be further developed for a variety of reasons. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TLANDO XR (LPCN 1111) is in a very early
stage of development. We have completed a Phase 2a and Phase 2b study in hypogonadal men. Results from the Phase 2a clinical study
demonstrated the feasibility of a once daily dosing with TLANDO XR (LPCN 1111) in hypogonadal men and a good dose response. Results
of the Phase 2b study suggest that the primary objectives were met, including identifying the dose expected to be tested in a Phase
3 study. Future studies may not have similar clinical results. Additionally, we have preliminary data demonstrating absorption
of TLANDO XR (LPCN 1111) in dogs and in postmenopausal females.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the active ingredient in TLANDO
XR (LPCN 1111) has only been manufactured on a small scale. Scaling up into larger batches could be challenging and our ability
to procure adequate material in a timely manner to further develop TLANDO XR (LPCN 1111) is uncertain. We also may not be able
to engage a manufacturer who can supply adequate quantities of the drug substance in compliance with Current Good Manufacturing
Practices (&quot;cGMP&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Several factors
could significantly affect the prospects for TLANDO XR (LPCN 1111), including factors relating to the regulatory approval and clinical
development challenges for TLANDO XR (LPCN 1111) discussed above. The anticipated Phase 3 program for an NDA filing for TLANDO
XR (LPCN 1111), however, could be very long and expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our research and development programs and processes are
at an early stage of development, which makes it difficult to evaluate our business and prospects, or predict if or when we will
successfully commercialize our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our operations to date have primarily been
limited to conducting research and development activities under license and collaboration agreements. Our current portfolio consists
of our most advanced product candidate TLANDO as well as four additional earlier stage clinical candidates, LPCN 1144, TLANDO XR
(LPCN 1111), LPCN 1148 and LPCN 1107. We have never marketed or commercialized a drug product. Consequently, any predictions about
our future performance may not be as accurate as they could be if we were further along our commercialization path. In addition,
as a pre-commercial stage business, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown
factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our clinical product candidates are at an
early stage of development and will require significant further investment and regulatory approvals prior to marketing and commercialization.
As such, our product development processes for TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 are very risky
and uncertain, and our product candidates may fail to advance beyond the current study. Even if we obtain required financing, we
cannot ensure successful product development or that we will obtain regulatory approval or successfully commercialize any of our
product candidates and generate product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to grow our company, and we may encounter
difficulties in managing this growth, which could disrupt our operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2019, we had 12 employees.
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems,
expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert
a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing
these growth activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations
or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion
of our operations may lead to significant costs and may divert financial resources from other projects. If our management is unable
to effectively manage our future growth, our expenses may increase more than expected, our ability to generate revenue could be
reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize
our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may have to dedicate resources to the defense and resolution
of litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Securities legislation
in the United States makes it relatively easy for stockholders to sue. This can lead to frivolous law suits which take substantial
time, money, resources and attention or force us to settle such claims rather than seek adequate judicial remedy or dismissal of
such claims. Historically, securities class action litigation has often been brought against a company following a decline in the
market price of its securities. Biotechnology and pharmaceutical companies, including the Company, have experienced significant
stock price volatility in recent years, increasing the risk of such litigation. As we defend the class action lawsuits or future
patent infringement actions should they be filed, or if we are required to defend additional actions brought by other shareholders,
we may be required to pay substantial litigation costs and managerial attention and financial resources may be diverted from business
operations even if the outcome is in our favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">On
July&nbsp;1, 2016, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,&nbsp;<I>David
Lewis v. Lipocine Inc et al</I>., 3:16-cv-04009-BRM-LHG, filed in the United States District Court for the District of New Jersey.
This initial action was followed by additional lawsuits also filed in the District of New Jersey. The lawsuits contain substantially
identical allegations and alleged that the defendants made false and/or misleading statements and/or failed to disclose that our
filing of the NDA for TLANDO to the FDA contained deficiencies and as a result the defendants&rsquo; statements about our business
and operations were false and misleading and/or lacked a reasonable basis in violation of federal securities laws. The lawsuits
sought certification as a class action, compensatory damages in an unspecified amount, and unspecified equitable or injunctive
relief. On February 15, 2018, the Company and the other defendants entered into a memorandum of understanding to settle the purported
securities class action litigation. On March 15, 2018, the Plaintiff filed a motion for preliminary approval of the settlement
along with a copy of the parties&rsquo; stipulation of settlement. On March 21, 2018, the court granted the motion for preliminary
approval of the settlement and amended the order on March 28, 2018. On July 2, 2018, the court issued the final order and approved
the settlement of $4.3 million as set forth in the parties&rsquo; stipulation. The order resolves all of the claims that were or
could have been brought in the action being settled. While our insurance carrier covered $3.6 million of the settlement, the Company&rsquo;s
capital resources are critical to its continued operations, and the payment of litigation settlements and associated legal fees
diverts these capital resources away from our operations, even if such amounts do not have a material impact on our financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On February 15,
2019, a purported shareholder filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware,&nbsp;<I>John
Wajda, derivatively on behalf of Lipocine Inc. v. Mahesh Patel, et al.,</I>&nbsp;against certain of the Company&rsquo;s current
and former officers and directors as well as the Company as a nominal defendant.&nbsp; The complaint asserts claims for alleged
breaches of fiduciary duty and unjust enrichment arising out of the Company&rsquo;s dissemination of purportedly false and misleading
statements relating to the filing of the NDA for TLANDO. &nbsp;The relief sought in the complaint includes unspecified damages,
changes to the Company&rsquo;s corporate governance procedures, equitable and/or injunctive relief, restitution, and attorneys&rsquo;
fees.&nbsp; On August 16, 2019, defendants filed a motion to dismiss the complaint. Plaintiff&rsquo;s response to the motion to
dismiss was due on October 18, 2019; however rather than file an opposition brief, plaintiffs filed an amended stockholder derivative
complaint. Defendants&rsquo; motion to dismiss the amended complaint is due on December 12, 2019; plaintiff&rsquo;s response is
due on January 27, 2020 and defendants&rsquo; reply is due on February 26, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.5in">On November 14, 2019, the Company
and certain of its officers were named as defendants in a purported shareholder class action lawsuit, <I>Solomon Abady v. Lipocine
Inc. et al</I>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint alleges that the
defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to the FDA contained
deficiencies and as a result the defendants&rsquo; statements about our business and operations were false and misleading and/or
lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&rsquo;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an
unspecified amount, and unspecified equitable or injunctive relief. We have insurance that covers claims of this nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Defendants
intend to vigorously defend themselves against these allegations, but doing so may result in substantial litigation costs and managerial
attention and financial resources may be diverted from business operations even if outcome is in favor of our current and former
officers and directors and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">We
also may be subject to additional types of litigation. On November 2, 2015, Clarus Therapeutics filed a complaint against us in
the United States District Court for the District of Delaware alleging that TLANDO will infringe Clarus&rsquo; 428 patent. The
Clarus complaint was dismissed by the District Court in 2016, because at the time there was no actionable infringement on Clarus&rsquo;
428 patent. Additionally on December 21, 2018, the PTAB granted Lipocine priority motion and entered adverse judgment against Clarus.
The PTAB ruling cancels all claims on the Clarus&rsquo; 428 Patent. However, Clarus appealed the PTAB judgement to the Court of
Appeals for the Federal Circuit on February 19, 2019. While the Clarus complaint has been dismissed and all their claims on the
Clarus&rsquo; 428 patent have been cancelled by the PTAB, the possibility remains that the decisions of the PTAB could be reversed
upon appeal. Additionally, Clarus could submit its claim again if TLANDO is approved by the FDA and enters the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 2, 2019, we filed a lawsuit against
Clarus in the United States District Court in Delaware alleging that Clarus&rsquo;s JATENZO&reg; product infringes six of Lipocine&rsquo;s
issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and 6,923,988. Clarus has answered the complaint and
asserted counterclaims of non-infringement and invalidity.&nbsp; We answered Clarus&rsquo;s counterclaims on April 29, 2019. &nbsp;The
Court held a scheduling conference on August 15, 2019 setting a claim construction hearing on February 11, 2020 and a five-day
jury trial beginning on August 24, 2020. On February 11, 2020, we also voluntarily dismissed allegations of patent infringement
for expired U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. The
parties are currently engaged in the fact discovery and claim construction phases of the lawsuit.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our financial
condition and results of operations for fiscal 2020 may be adversely affected by the recent coronavirus outbreak.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2019, a novel strain of coronavirus
was reported to have surfaced in Wuhan, China. At the time of this filing, the outbreak has been most concentrated in China, although
cases have been confirmed in other countries. Our operations could be adversely affected to the extent that coronavirus or any
other epidemic harms the Chinese or world economy in general. Our operation may experience disruptions, such as temporary closure
of our offices and/or suspension of services, which may materially and adversely affect our business, financial condition and results
of operations. The duration of the business disruption and related financial impact cannot be reasonably estimated at this time
but may materially affect our ability to operate our business and result in additional costs. The extent to which the coronavirus
or other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted,
including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus
or treat its impact, among others.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our management and directors will be able to exert influence
over our affairs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2019, our executive officers
and directors beneficially owned approximately 8.4% of our common stock. These stockholders, if they act together, may be able
to influence our management and affairs and all matters requiring stockholder approval, including significant corporate transactions.
This concentration of ownership may have the effect of delaying or preventing a change in control and might affect the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our common stock is thinly traded, may continue to be
thinly traded in the future, and our stockholders may be unable to sell at or near asking prices or at all if they need to sell
their shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, we have a low volume of daily
trades in our common stock on NASDAQ. For example, the average daily trading volume in our common stock on NASDAQ during the fourth
quarter of 2019 was approximately 707,000 shares per day. Our stockholders may be unable to sell their common stock at or near
their asking prices or at all, which may result in substantial losses to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market for our common stock may be characterized
by significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile than
a seasoned issuer for the indefinite future. As noted above, our common stock may be sporadically and/or thinly traded. As a consequence
of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence
the price of those shares in either direction. The price for our shares could, for example, decline significantly in the event
that a large number of shares of our common stock are sold on the market without commensurate demand, as compared to a seasoned
issuer that could better absorb those sales without adverse impact on its share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We may not be able to maintain
our listing on the NASDAQ Capital Market, which would adversely affect the price and liquidity of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">As a small capitalization
pharmaceutical company, the price of our common shares has been, and is likely to continue to be, highly volatile. Any announcements
concerning us or our competitors, clinical trial results, quarterly variations in operating results, introduction of new products,
delays in the introduction of new products or changes in product pricing policies by us or our competitors, acquisition or loss
of significant customers, partners and suppliers, changes in earnings estimates or our ratings by analysts, regulatory developments,
or fluctuations in the economy or general market conditions, among other factors, could cause the market price of our common shares
to fluctuate substantially. There can be no assurance that the market price of our common shares will not decline below its current
price or that it will not experience significant fluctuations in the future, including fluctuations that are unrelated to our performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Currently our
common stock is quoted on the NASDAQ Capital Market under the symbol &ldquo;LPCN&rdquo;. We must satisfy certain minimum listing
maintenance requirements to maintain the NASDAQ Capital Market quotation, including certain governance requirements and a series
of financial tests relating to stockholders equity or net income or market value, public float, number of market makers and stockholder,
market capitalization, and maintaining a minimum bid price of $1.00 per share. On December 27, 2019, we received a notice from
the Listing Qualifications Department of The NASDAQ Stock Market stating that for the last thirty consecutive business days the
bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital
Market under NASDAQ Listing Rule 5550(a)(2). In accordance with NASDAQ Listing Rule 5810 (c)(3)(A), we were provided an initial
period of 180 calendar days, or until June 24, 2020, to regain compliance. If we do not regain compliance by June 24, 2020, we
may be eligible for an additional 180 calendar days to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">If we do not regain
compliance with Rule 5550(a)(2), the Staff will provide written notification to us that our common stock will be delisted. At that
time, we may appeal the Staff&rsquo;s delisting determination to a NASDAQ Hearings Panel, or the Panel. We would remain listed
pending the Panel&rsquo;s decision. There can be no assurance that, if we do appeal the delisting determination by the Staff to
the Panel, that such appeal would be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>The aggregate fair value of the
warrant liability included in the Company&rsquo;s consolidated balance sheet of our warrants outstanding from the November Offering
is subject to potentially material increases and decreases based on fluctuations in the price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In November 2019,
we completed a public offering of common stock and warrants to purchase common stock. Gross proceeds from the November Offering
were approximately $6.0 million. In the November Offering, we sold (i) 10,450,000 Class A Units, each Class A Unit consisted of
one share of its common stock and a common warrant to purchase its common stock, and (ii) 1,550,000 Class B Units, each Class B
Unit consisting of one pre-funded warrant and a common stock warrant to purchase its common stock, at a price of $0.50 per Class
A Unit and $0.4999 per Class B Unit. The pre-funded warrants were issued in lieu of common stock in order to ensure the purchaser
did not exceed certain beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price
of $0.0001 per share, subject to adjustment. Additionally, the common stock warrants were immediately exercisable at an exercise
price of $0.50 per share and expire on November 17, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We account for
the warrants as a derivative instrument, and changes in the fair value of the warrants are included under other income (expense)
in the Company&rsquo;s statements of operations for each reporting period. At December&nbsp;31, 2019, the aggregate fair value
of the warrant liability included in the Company&rsquo;s consolidated balance sheet was $4.6 million. We use the Black-Scholes
option pricing model to determine the fair value of the warrants. As a result, the option-pricing model requires the input of several
assumptions, including the stock price volatility, share price and risk-free interest rate. Changes in these assumptions can materially
affect the fair value estimate. While the liability may only result from a change of control at that point in time, we ultimately
may incur amounts significantly different than the carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in"><B></B></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in"><B>&nbsp;</B></P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RISKS RELATING TO OUR FINANCIAL POSITION AND CAPITAL REQUIREMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need substantial additional capital in the future.
If additional capital is not available, we will have to delay, reduce or cease operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will need to raise additional capital
to continue to fund our operations. Our future capital requirements may be substantial and will depend on many factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>current and future clinical trials for our product candidates, including for LPCN 1144;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to respond to the CRLs we have received from the FDA;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory actions of the FDA, particularly related to TLANDO;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope, size, rate of progress, results and costs of completing ongoing clinical trials and development plans with our product
candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost, timing and outcomes of our efforts to obtain marketing approval for our product candidates in the United States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>payments received under any license agreements, strategic partnerships or collaborations that we may enter into in the future,
if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost of filing, prosecuting and enforcing patent claims;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs associated with commercializing our product candidates if we receive marketing approval, including the cost and timing
of developing internal sales and marketing capabilities or entering into strategic collaborations to market and sell our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs of on-going and future litigation; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>funding additional product line expansions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that our existing capital resources,
together with interest thereon, will be sufficient to meet our projected operating requirements through at least September 30,
2020. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources
sooner than we currently expect. While we believe we have sufficient liquidity and capital resources to fund our projected operating
requirements through at least September 30, 2020, we will need to raise additional capital at some point through the equity or
debt markets or through out-licensing activities, either before or after September 30, 2020, to support our operations, on-going
clinical study for LPCN 1144, on-going intellectual property litigation and compliance with regulatory requirements. If the Company
is unsuccessful in raising additional capital its ability to continue as a going concern will become a risk. Further, our operating
plan may change, and we may need additional funds to meet operational needs and capital requirements for product development, regulatory
compliance and clinical trial activities sooner than planned. In addition, our capital resources may be consumed more rapidly if
we pursue additional clinical studies for LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107. Conversely, our capital resources
could last longer if we reduce expenses, reduce the number of activities currently contemplated under our operating plan or if
we terminate or suspend on-going clinical studies or intellectual property litigation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Funding may not be available to us on favorable
terms, or at all. Also, market conditions may prevent us from accessing the debt and equity capital markets, including sales of
our common stock through the ATM Offering (as defined below). If we are unable to obtain adequate financing when needed, we may
have to delay, reduce the scope of or suspend one or more of our clinical studies, research and development programs or, if any
of our product candidates receive approval from the FDA, commercialization efforts. We may seek to raise any necessary additional
capital through a combination of public or private equity offerings, including the ATM Offering, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements. These arrangements may not be available
to us or available on terms favorable to us. To the extent that we raise additional capital through marketing and distribution
arrangements, other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or grant licenses on
terms that may not be favorable to us. If we do raise additional capital through public or private equity offerings, the ownership
interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences,
warrants or other terms that adversely affect our stockholders&rsquo; rights or further complicate raising additional capital in
the future. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability
to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable,
for any reason, to raise needed capital, we will have to reduce costs, delay research and development programs, liquidate assets,
dispose of rights, commercialize products or product candidates earlier than planned or on less favorable terms than desired or
reduce or cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have incurred significant operating losses in most
years since our inception and anticipate that we will incur continued losses for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have focused a significant portion of
our efforts on developing TLANDO. We have funded our operations to date through sales of our equity securities, debt and payments
received under our license and collaboration arrangements from sales of common stock, preferred stock and convertible debt and
from license and milestone revenues and research revenue from license and collaboration agreements with corporate partners. We
have incurred losses in most years since our inception. As of September 30, 2019, we had an accumulated deficit of $147.8&nbsp;million.
Substantially all of our operating losses resulted from costs incurred in connection with our research and development programs
and from general and administrative costs associated with our operations. These losses, combined with expected future losses, have
had and will continue to have an adverse effect on our stockholders&rsquo; equity and working capital. We expect our research and
development expenses to significantly increase in connection with clinical trials associated with LPCN 1144, TLANDO XR (LPCN 1111),
LPCN 1148 and LPCN 1107, if initiated. In addition, if we eventually obtain marketing approval for TLANDO, we will incur significant
sales, marketing and commercialization expenses. As a result, we expect to continue to incur significant operating losses for the
foreseeable future as we evaluate our options with TLANDO and further clinical development of LPCN 1144, TLANDO XR (LPCN 1111),
LPCN 1148, LPCN 1107 and our other programs and continued research efforts. Because of the numerous risks and uncertainties associated
with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that the net proceeds from this
offering will be approximately $5.6 million, after deducting the placement agent&rsquo;s commissions and estimated expenses of
the offering payable by us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to use the net proceeds from this
offering for general corporate purposes. General corporate purposes may include additions to working capital and capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will retain broad discretion over the
use of the net proceeds from the sale of the securities offered hereby. Accordingly, we reserve the right to use these proceeds
for different purposes or uses which we have not listed above. See &ldquo;Risk Factors &ndash; <I>Since we have broad discretion
in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until we use the net proceeds of this offering,
we intend to invest the funds in investment grade, interest-bearing securities or hold such proceeds in deposit accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth our cash, cash equivalents and capitalization as of September 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">on an as adjusted basis to give effect to the assumed issuance
and sale of&nbsp;all Class A Units in this offering at the public offering price of $0.595 per Class A Unit (but excluding shares
of common stock to be issued and any proceeds received upon exercise of the common stock purchase warrants), after deducting estimated
placement agent&rsquo;s fees, and estimated offering expenses payable by us.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This capitalization table should be read
in conjunction with the section entitled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations&rdquo; and our financial statements and related notes included in our Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2019 and incorporated by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> September 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As <BR> Adjusted</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,664,508</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12,289,508</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Marketable investment securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,880,876</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,880,876</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current portion of long-term debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,333,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,333,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Non-current portion of long-term debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,601,837</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,601,837</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stockholders&rsquo; Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Preferred stock, $0.0001 par value, 10,000,000 authorized; zero issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Common stock, $0.0001 par value, 100,000,000 shares authorized and 25,033,482 issued and 25,027,772 outstanding, actual; and 35,119,116 issued and 35,111,806 outstanding, as adjusted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,503</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,511</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">155,318,402</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">160,942,394</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Treasury stock at cost, 5,710 shares actual and as adjusted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(40,712</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(40,712</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accumulated other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">261</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">261</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(147,775,114</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(147,775,114</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,505,340</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,130,340</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the table above, the number of shares
outstanding as of September 30, 2019 does not include (i) 2,310,485 options to purchase shares of our common stock issued under
our Third Amended and Restated 2014 Stock and Incentive Plan and our 2011 Equity Incentive Plan, (ii) 678,687 unvested restricted
stock units of our common stock issued under our Third Amended and Restated 2014 Stock and Incentive Plan, (iii) 10,450,000 shares
of common stock issued in a public offering in November 2019, and (iv) 13,550,000 shares of common stock underlying warrants issued
in a public offering in November 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Purchasers of shares of our common stock
in this offering will suffer an immediate and substantial dilution in net tangible book value per share. Net tangible book value
per share is total tangible assets, reduced by total liabilities, divided by the total number of outstanding shares of common stock.
Our net tangible book value as of September 30, 2019 was approximately $7.5 million, or approximately $0.30 per outstanding share
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After giving effect to the issuance and
sale of all Class A Units in this offering at the public offering price of $0.595&nbsp;per Class A Unit (but excluding shares of
common stock to be issued and any proceeds received upon exercise of the common stock purchase warrants), and after deducting estimated
placement agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of September 30,
2019 would have been approximately $13.1 million, or $0.374 per share. This represents an immediate increase in net tangible book
value of $0.074 per share to existing stockholders and immediate dilution of $0.221 per share to investors purchasing our common
stock in this offering at the public offering price. The following table illustrates this calculation on a per share basis:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in; margin-right: 0.25in">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 66%"><FONT STYLE="font-size: 10pt">Public offering price per Unit</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">0.595</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net tangible book value per share as of September 30, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.300</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Increase in net tangible book value per share after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.074</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">As adjusted net tangible book value per share as of September 30, 2019, after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.374&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dilution in as adjusted net tangible book value per share to new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">0.221&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The above discussion is based on 25,027,772
shares of common stock outstanding as of September 30, 2019, and does not include (i) 2,310,485 options to purchase shares of our
common stock issued under our Third Amended and Restated 2014 Stock and Incentive Plan and our 2011 Equity Incentive Plan, (ii)
678,687 unvested restricted stock units of our common stock issued under our Third Amended and Restated 2014 Stock and Incentive
Plan, (iii) 10,450,000 shares of common stock issued in a public offering in November 2019, and (iv) 13,550,000 shares of common
stock underlying warrants issued in a public offering in November 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">We
are offering 10,084,034&nbsp;Class A Units, each Class A Unit consisting of one share of our common stock, and one-half of one
common stock purchase warrant to purchase shares of common stock. The common stock and common stock purchase warrants included
in each Class A Unit will be issued separately. Units will not be issued or certificated. We are also registering the shares of
common stock included in the Class A Units and the shares of common stock issuable from time to time upon exercise of common stock
purchase warrants included in the Class A Units. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A description of the Common Stock we are
offering pursuant to this prospectus supplement is set forth under the heading &ldquo;Description of Capital Stock&mdash;Common
Stock&rdquo; beginning on page 8 of the accompanying prospectus. As of February 24, 2020, we had 37,649,465 shares of Common Stock
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock Purchase Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The material terms and provisions of the
common stock purchase warrants being offered pursuant to this prospectus are summarized below. This summary of some provisions
of the common stock purchase warrants is not complete. For the complete terms of the common stock purchase warrants, you should
refer to the form of common stock purchase warrant filed as an exhibit to the Current Report on Form 8-K filed on the date hereof.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each whole common stock purchase warrant
is exercisable to purchase one share of our Common Stock at an exercise price of $0.53 per share at any time for up to five&nbsp;years
after the date of the closing of this offering. The holder of a common stock purchase warrant will not be deemed a holder of our
underlying common stock until the common stock purchase warrant is exercised, except as set forth in the common stock purchase
warrant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to limited exceptions, a holder
of common stock purchase warrants will not have the right to exercise any portion of its common stock purchase warrants if the
holder (together with such holder&rsquo;s affiliates, and any persons acting as a group together with such holder or any of such
holder&rsquo;s affiliates) would beneficially own a number of shares of our common stock in excess of 4.99% (or, at the election
of the holder, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise (the &ldquo;Beneficial
Ownership Limitation&rdquo;); provided, however, that upon notice to the Company, the holder may increase or decrease the Beneficial
Ownership Limitation, provided that in no event shall the Beneficial Ownership Limitation exceed 9.99% and any increase in the
Beneficial Ownership Limitation will not be effective until 61 days following notice of such increase from the holder to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise price and the number of shares
issuable upon exercise of the common stock purchase warrants is subject to appropriate adjustment in the event of recapitalization
events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common
stock. The holders of common stock purchase warrants must pay the exercise price in cash upon exercise of the common stock purchase
warrants, unless such holders are utilizing the cashless exercise provision of the common stock purchase warrants, which is only
available in certain circumstances such as if the underlying shares are not registered with the SEC pursuant to an effective registration
statement. We intend to use commercially reasonable efforts to have the registration statement of which this prospectus forms a
part, effective when the common stock purchase warrants are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, in the event we consummate
a merger or consolidation with or into another person or other reorganization event in which our common shares are converted or
exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or otherwise dispose of
all or substantially all of our assets or we or another person acquire 50% or more of the outstanding shares of our common stock,
then following such event, the holders of the common stock purchase warrants will be entitled to receive upon exercise of the common
stock purchase warrants the same kind and amount of securities, cash or property which the holders would have received had they
exercised the common stock purchase warrants immediately prior to such fundamental transaction. Any successor to us or surviving
entity shall assume the obligations under the common stock purchase warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Roth Capital Partners, LLC, which we refer
to herein as the placement agent, has agreed to act as our exclusive placement agent in connection with this offering subject to
the terms and conditions of the placement agency agreement dated February 25, 2020. The placement agent is not purchasing or selling
any of the securities offered by this prospectus supplement, nor is it required to arrange the purchase or sale of any specific
number or dollar amount of shares of our common stock, but has agreed to use its reasonable best efforts to arrange for the sale
of all of the Class A Units offered hereby. Therefore, we will enter into a securities purchase agreement directly with institutional
investors in connection with this offering. Investors who do not enter into a securities purchase agreement shall rely solely on
this prospectus supplement in connection with the purchase of our securities in this offering. The placement agency agreement does
not give rise to any commitment by the placement agent to purchase any of our units, and the placement agent will have no authority
to bind us by virtue of the placement agency agreement. Further, the placement agent does not guarantee that it will be able to
raise new capital in any prospective offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will deliver the securities underlying
the Class A Units being issued to the investors upon receipt of investor funds for the purchase of the Class A Units offered pursuant
to this prospectus. We expect to deliver the shares of our common stock being offered pursuant to this prospectus on or about February
27, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Fees and Expenses </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to pay the placement agent
a cash fee equal to 5.5% of the aggregate purchase price of the securities sold in this offering. The following table shows the
per Unit and total cash placement agent's fees we will pay to the placement agent in connection with the sale of the Class A Units
offered pursuant to this prospectus supplement and the accompanying prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Class A Unit</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt">Public offering price</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">0.595000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">6,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Placement Agent&rsquo;s fees payable by us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.032725</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">330,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.562275</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,670,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that the total expenses of the
offering payable by us, excluding the placement agent fees and expenses will be approximately $45,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The placement agent may be deemed to be
an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act, and any commissions received by it and any profit
realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions
under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities
Act and the Exchange Act, including, without limitation, Rule&nbsp;415(a)(4) under the Securities Act and Rule&nbsp;10b-5 and Regulation&nbsp;M
under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the placement agent
acting as principal. Under these rules and regulations, the placement agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">may not engage in any stabilization activity in connection with our securities; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to indemnify the placement
agent and specified other persons against some civil liabilities, including liabilities under the Securities Act, and the Exchange
Act, and to contribute to payments that the placement agent may be required to make in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Discretionary Accounts </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The placement agent does not intend to confirm
sales of the securities offered hereby to any accounts over which it has discretionary authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our officers and directors have
agreed with the placement agent to be subject to a lock-up period of 60 days following the closing date of this offering. This
means that, during the applicable lock-up period, we may not offer for sale, contract to sell, or sell any shares of our common
stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock subject to certain customary
exception such as issuing stock options to directors, officers, employees and consultants under our existing plan and issuances
of shares issuable upon the exercise of our outstanding warrants, including the warrants issued pursuant to this prospectus supplement.
The placement agent may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements. We have
also agreed in the securities purchase agreement to similar restrictions on the sale of our securities for a period of 60 days
following the closing date of this offering. The purchasers party to the securities purchase agreements may, in their sole discretion
and without notice, waive the terms of the company lock-up agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Leak-Out Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each institutional investor who enters into
the securities purchase agreement will also enter into a Leak-Out Agreement with the Company (each, a &ldquo;Leak-Out Agreement&rdquo;
and collectively, the &ldquo;Leak-Out Agreements&rdquo;) wherein each investor who is party to a Leak-Out Agreement (together with
certain of its affiliates) will agree to not sell, dispose or otherwise transfer, directly or indirectly (including, without limitation,
any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or short positions), on any
trading day from the public announcement of the offering and ending at 4:00 pm (New York City time) on March 10, 2020, shares of
common stock, or shares of common stock underlying any common stock equivalents held by such investor on the date of the Leak-Out
Agreements, including shares underlying the warrants, in an amount more than its pro rata portion of 25% of the trading volume
of the common stock (increasing to 35% for sales by the holder at a price per share between $0.60 and $0.70), subject to certain
exceptions. This restriction will not apply to any actual &ldquo;long&rdquo; (as defined in Regulation SHO promulgated under the
Securities Exchange Act of 1934, as amended) sales by such investor (together with certain of its affiliates) at or above $0.70
or to any long sales of shares of common stock purchased in open market transactions by such investor (together with certain of
its affiliates) during the restricted period. Further, this restriction will not apply to sales or transfers of any such shares
of common stock in transactions which do not need to be reported on the Nasdaq consolidated tape so long as the purchaser or transferee
executes and delivers a Leak-Out Agreement. After such sale or transfer, future sales of the securities covered by the Leak-Out
Agreement by the original owner (together with certain of its affiliates) and the purchaser or transferee will be aggregated to
determine compliance with the terms of the Leak-Out Agreements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on the NASDAQ
Capital Market under the symbol &ldquo;LPCN.&rdquo; There is no established public trading market for the warrants, and we do not
expect a trading market to develop. In addition, we do not intend to apply for listing of the warrants on any securities exchange
or recognized trading system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent
for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain legal matters in connection with
the offering and the validity of the securities offered by this prospectus supplement will be passed upon for us by Dorsey&nbsp;&amp;
Whitney LLP, Salt Lake City, Utah. Ellenoff Grossman &amp; Schole LLP, New York, New York is acting as counsel for the placement
agent in connection with certain legal matters in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of
Lipocine Inc. as of December 31, 2018 and for the one-year period ended December 31, 2018 have been incorporated by reference herein
and in the registration statement in reliance upon the report of Tanner LLC, independent registered public accounting firm, incorporated
by reference herein, and upon authority of said firm as experts in accounting and auditing. The consolidated financial statements
of Lipocine Inc. as of December 31, 2017, and for each of the years in the two-year period ended December 31, 2017, have been incorporated
by reference herein and in the registration statement in reliance upon the reports of KPMG LLP, independent registered public accounting
firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a reporting company and file annual,
quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement
on Form S-3 under the Securities Act with respect to the securities we are offering under this prospectus supplement and the accompanying
prospectus. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration
statement and the exhibits to the registration statement. For further information with respect to us and the securities we are
offering under this prospectus supplement and the accompanying prospectus, we refer you to the registration statement and the exhibits
and schedules filed as a part of the registration statement. The SEC maintains an internet site that contains reports, proxy and
information statements, and other information regarding issuers that file electronically with the SEC, where our SEC filings are
also available. The address of the SEC&rsquo;s web site is http://www.sec.gov. We maintain a website at www.lipocine.com. Information
contained in or accessible through our website does not constitute a part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information that we file with it into this prospectus supplement and the accompanying prospectus, which means
that we can disclose important information to you by referring you to those documents. The information incorporated by reference
is an important part of this prospectus supplement and the accompanying prospectus. The information incorporated by reference is
considered to be a part of this prospectus supplement and the accompanying prospectus, and information that we file later with
the Commission will automatically update and supersede information contained in this prospectus supplement and the accompanying
prospectus. We incorporate by reference the documents listed below that we have previously filed with the Commission:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419012434/tv514295_10k.htm" STYLE="-sec-extract: exhibit">our Annual Report on Form 10-K for the year ended December 31, 2018</A> (<A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419022112/tv519385_def14a.htm" STYLE="-sec-extract: exhibit">including the portions of our Proxy Statement on Schedule 14A for our 2019 Annual Meeting, filed with the SEC on April 30, 2019, that are incorporated by reference therein</A>);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419024378/tv519604_10q.htm" STYLE="-sec-extract: exhibit">our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019</A>;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419024378/tv519604_10q.htm" STYLE="-sec-extract: exhibit">our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019</A>;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919062585/tm1919550-1_10q.htm" STYLE="-sec-extract: exhibit">our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019</A>;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419000774/tv510459_8k.htm" STYLE="-sec-extract: exhibit">January
    7, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419001492/tv510926_8k.htm" STYLE="-sec-extract: exhibit">January
    14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419001913/tv511184_8k.htm" STYLE="-sec-extract: exhibit">January
    17, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419002177/tv511294_8-k.htm" STYLE="-sec-extract: exhibit">January
    22, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419002508/tv511452_8-k.htm" STYLE="-sec-extract: exhibit">January
    24, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419002959/tv511699_8k.htm" STYLE="-sec-extract: exhibit">January
    28, 2019</A>,<A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419007530/tv513625_8k.htm" STYLE="-sec-extract: exhibit">February
    14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419012435/tv515354_8k.htm" STYLE="-sec-extract: exhibit">March
    6, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419012674/tv515397_8k.htm" STYLE="-sec-extract: exhibit">March
    7, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419013395/tv515982_8k.htm" STYLE="-sec-extract: exhibit">March
    12, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419014460/tv516327_8k.htm" STYLE="-sec-extract: exhibit">March
    18, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419015861/tv516785_8k.htm" STYLE="-sec-extract: exhibit">March
    26, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419016088/tv517244_8k.htm" STYLE="-sec-extract: exhibit">March
    27, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419016413/tv517250_8k.htm" STYLE="-sec-extract: exhibit">March
    28, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419017898/tv517941_8k.htm" STYLE="-sec-extract: exhibit">April
    3, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419019156/tv516915_8k.htm" STYLE="-sec-extract: exhibit">April
    11, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419022665/tv520110_8k.htm" STYLE="-sec-extract: exhibit">May
    1, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419024380/tv520767_8k.htm" STYLE="-sec-extract: exhibit">May
    8, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419025779/tv521534_8k.htm" STYLE="-sec-extract: exhibit">May
    14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419028428/tv522552_8k.htm" STYLE="-sec-extract: exhibit">May
    28, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419030684/tv523486_8k.htm" STYLE="-sec-extract: exhibit">June
    12, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419032049/tv524107_8k.htm" STYLE="-sec-extract: exhibit">June
    24, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419035466/tv525541_8k.htm" STYLE="-sec-extract: exhibit">July
    23, 2019 (with respect to Item 8.01 only)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419038040/tv526829_8-k.htm" STYLE="-sec-extract: exhibit">August
    7, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419041715/tv528342_8k.htm" STYLE="-sec-extract: exhibit">August
    27, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419045547/tv529810_8k.htm" STYLE="-sec-extract: exhibit">September
    23, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419045549/tv529846_8k.htm" STYLE="-sec-extract: exhibit">September
    23, 2019 (with respect to Item 8.01 only)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419046380/tv529812_8k.htm" STYLE="-sec-extract: exhibit">September
    30, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420419046623/tv530209_8k.htm" STYLE="-sec-extract: exhibit">October
    1, 2019 (with respect to Item 8.01 only)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919055092/tm1920391d1_8k.htm" STYLE="-sec-extract: exhibit">October
    21, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919055094/tm1920614d1_8k.htm" STYLE="-sec-extract: exhibit">October
    21, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919056511/tm1920994d1_8k.htm" STYLE="-sec-extract: exhibit">October
    25, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919061367/tm1922020d1_8k.htm" STYLE="-sec-extract: exhibit">November
    8, 2019 (with respect to Item 8.01 only)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919061976/tm1922433d1_8k.htm" STYLE="-sec-extract: exhibit">November
    12, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919063293/tm1922702d1_8k.htm" STYLE="-sec-extract: exhibit">November
    13, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919063788/tm1922709-2_8k.htm" STYLE="-sec-extract: exhibit">November
    14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919063788/tm1922709-2_8k.htm" STYLE="-sec-extract: exhibit">November
    14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465919076463/tm1927520d1_8k.htm" STYLE="-sec-extract: exhibit">December
    27, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465920003237/tm201752d1_8k.htm" STYLE="-sec-extract: exhibit">January
    13, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465920016289/tm207311d1_8k.htm" STYLE="-sec-extract: exhibit">February
    11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465920024088/tm209591d1_8k.htm" STYLE="-sec-extract: exhibit">February
    24, 2020</A><FONT STYLE="font-family: Times New Roman, Times, Serif">, and <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000110465920024503/tm2010873d1_8k.htm" STYLE="-sec-extract: exhibit">February
    25, 2020</A>; </FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420414016287/v371993_8a12b.htm" STYLE="-sec-extract: exhibit">the description of our common stock contained on our Registration Statement on Form 8-A filed with the SEC on March 18, 2014</A>, including any amendments or reports filed for the purpose of updating such description.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also incorporate by reference into this
prospectus supplement additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act before our offering is terminated or completed, excluding, in each case, information deemed furnished and not filed. Any statements
contained in a previously filed document incorporated by reference into this prospectus supplement is deemed to be modified or
superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement, or
in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will provide to each person, including
any beneficial owner, to whom a prospectus supplement is delivered, without charge upon written or oral request, a copy of any
or all of the information that has been incorporated by reference into this prospectus supplement but not delivered with the prospectus
supplement, including exhibits that are specifically incorporated by reference into such documents. Requests should be directed
to: Lipocine Inc., Attention: Investor Relations, 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108, telephone: (801) 994-7383.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_015"></A>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$150,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock, Preferred Stock,<BR>
Debt Securities,<BR>
Warrants and Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, we may offer and sell
up to $150,000,000 of any combination of the securities described in this prospectus, either individually or in combination. We
may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock,
or common stock, preferred stock or debt securities upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus provides a general description
of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these
offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained
in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as any documents incorporated by reference in this prospectus before you invest in any securities. This prospectus
may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on the NASDAQ
Capital Market under the symbol &ldquo;LPCN&rdquo;. On November 16, 2017, the last reported sale price for our common stock was
$3.85 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the
NASDAQ Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>INVESTING IN OUR SECURITIES INVOLVES
RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &ldquo;RISK FACTORS&rdquo; ON PAGE 5
AND CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS AND UNDER SIMILAR HEADINGS IN THE
OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The securities may be sold directly to investors,
through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods
of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus. If any underwriters or
agents are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters
or agents and any applicable commissions or discounts and over-allotment options will be set forth in a prospectus supplement.
The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is November
21, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 90%"><A HREF="#a_016"><FONT STYLE="font-size: 10pt; text-transform: uppercase">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">i</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_017"><FONT STYLE="font-size: 10pt; text-transform: uppercase">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">ii</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_018"><FONT STYLE="font-size: 10pt; text-transform: uppercase">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_019"><FONT STYLE="font-size: 10pt; text-transform: uppercase">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_020"><FONT STYLE="font-size: 10pt; text-transform: uppercase">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_021"><FONT STYLE="font-size: 10pt; text-transform: uppercase">RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK DIVIDENDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_021"><FONT STYLE="font-size: 10pt; text-transform: uppercase">7</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_022"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_022"><FONT STYLE="font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_023"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_023"><FONT STYLE="font-size: 10pt">12</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_024"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_024"><FONT STYLE="font-size: 10pt; text-transform: uppercase">13</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_025"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_025"><FONT STYLE="font-size: 10pt; text-transform: uppercase">15</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_026"><FONT STYLE="font-size: 10pt; text-transform: uppercase">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_026"><FONT STYLE="font-size: 10pt">16</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_027"><FONT STYLE="font-size: 10pt; text-transform: uppercase">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_027"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_028"><FONT STYLE="font-size: 10pt; text-transform: uppercase">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_028"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_029"><FONT STYLE="font-size: 10pt; text-transform: uppercase">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_029"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_030"><FONT STYLE="font-size: 10pt; text-transform: uppercase">INCORPORATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_030"><FONT STYLE="font-size: 10pt">20</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_016"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">References in this prospectus and the documents
incorporated by reference to the &ldquo;Company,&rdquo; &ldquo;Lipocine,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; or &ldquo;we&rdquo;
refer to Lipocine Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is a part of a registration
statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a &ldquo;shelf&rdquo; registration process.
Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more
offerings up to a total dollar amount of $150,000,000. This prospectus provides you with a general description of the securities
we may offer. Each time we sell securities under this shelf registration, we will provide a prospectus supplement that will contain
specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided
to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing
prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable
prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as
described under the heading &ldquo;Incorporation by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information
that we have provided or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to
give any information or to make any representation other than those contained or incorporated by reference in this prospectus,
any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must
not rely upon any information or representation not contained or incorporated by reference in this prospectus or the accompanying
prospectus supplement. This prospectus and the accompanying supplement to this prospectus do not constitute an offer to sell or
the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus
and the accompanying supplement to this prospectus constitute an offer to sell or the solicitation of an offer to buy securities
in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not
assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus
is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated
by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus,
any applicable prospectus supplement or any related free writing prospectus is delivered or securities sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_017"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the documents incorporated
by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties. Forward-looking statements
provide current expectations of future events based on certain assumptions and include any statement that does not directly relate
to any historical or current fact. Forward-looking statements may refer to such matters as products, product benefits, pre-clinical
and clinical development timelines, clinical and regulatory expectations and plans, regulatory developments and requirements, the
receipt of regulatory approvals, the results of clinical trials, patient acceptance of Lipocine&rsquo;s products, manufacturing
and commercialization of Lipocine&rsquo;s products, anticipated financial performance, future revenues or earnings, business prospects,
projected ventures, new products and services, anticipated market performance, future expectations for liquidity and capital resources
needs and similar matters. These are based on our management&rsquo;s current beliefs, expectations and assumptions about future
events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements
may be found, among other places, in the Sections of this prospectus entitled &ldquo;Prospectus Summary&rdquo; and &ldquo;Risk
Factors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All statements, other than statements of
historical fact, included or incorporated herein regarding our strategy, future operations, financial position, future revenues,
projected costs, plans, prospects and objectives are forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
 &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions. These statements involve risks, uncertainties
and other factors that may cause our actual results, performance, time frames or achievements to be materially different from any
future results, performance, time frames or achievements expressed or implied by the forward-looking statements. Risks, uncertainties
and other factors that might cause or contribute to such differences include, but are not limited to, those discussed in the Section
entitled &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Given these
risks, uncertainties and other factors, many of which are beyond our control, you should not place undue reliance on these forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, past financial and/or operating
performance is not necessarily a reliable indicator of future performance and you should not use our historical performance to
anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking
statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Except
as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking
statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_018"></A>Prospectus
Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This summary highlights selected information
from this prospectus and does not contain all of the information that you need to consider in making your investment decision.
You should carefully read the entire prospectus, including the risks of investing discussed under &ldquo;Risk Factors&rdquo; beginning
on page 5, the information incorporated by reference, including our financial statements, and the exhibits to the registration
statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview of Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a specialty pharmaceutical company
focused on applying our oral drug delivery technology for the development of pharmaceutical products in the area of men&rsquo;s
and women&rsquo;s health. Our proprietary delivery technologies are designed to improve patient compliance and safety through orally
available treatment options. Our primary development programs are based on oral delivery solutions for poorly bioavailable drugs.
We have a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (&ldquo;PK&rdquo;) characteristics
and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal
interactions that limit bioavailability. Our lead product candidate, TLANDO&trade; or LPCN 1021, is an oral testosterone replacement
therapy (&ldquo;TRT&rdquo;) and is currently under review by the United States Food and Drug Administration (&ldquo;FDA&rdquo;)
with a Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;) action goal date of May 8, 2018. The FDA has deemed the resubmission
a complete response to its June 2016 Complete Response Letter (&ldquo;CRL&rdquo;) that requested additional information related
to the dosing algorithm for the proposed label. The TLANDO New Drug Application (&ldquo;NDA&rdquo;) is based on the results of
the Dosing Validation (&ldquo;DV&rdquo;<B>)&nbsp;</B>study. The DV study confirmed the efficacy of TLANDO with a fixed dose regimen
without need for dose adjustment. TLANDO was well tolerated upon 52-week exposure with no reports of drug related Serious Adverse
Events (&ldquo;SAEs&rdquo;). Additionally, the Bone, Reproductive and Urologic Drugs Advisory Committee (&ldquo;BRUDAC&rdquo;)
of the FDA plans to discuss the NDA for TLANDO on January 10, 2018. Although there is no guarantee of approval of TLANDO, we believe
the results from the DV study confirm the validity of a fixed dose approach without the need for dose titration to orally administering
LPCN 1021. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with the potential
for once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone
caproate product indicated for the prevention of recurrent preterm birth, and has completed an End-of-Phase 2 meeting with the
FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have funded our operations primarily
through the sale of equity securities and convertible debt and through up-front payments, research funding and milestone payments
from our license and collaboration arrangements. We have not generated any revenues from product sales and we do not expect to
generate revenue from product sales unless and until we obtain regulatory approval of TLANDO or other products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred losses in most years since
our inception. Substantially all of our operating losses resulted from expenses incurred in connection with our product candidate
development programs, our research activities and general and administrative costs associated with our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to continue to incur significant
expenses and operating losses for the foreseeable future as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">prepare for an FDA Advisory Committee meeting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">conduct further development of our other product candidates, including LPCN 1111 and LPCN 1107;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">continue our research efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">maintain, expand and protect our intellectual property portfolio;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">expand our marketing and sales efforts as we perform pre-commercialization activities; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provide general and administrative support for our operations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To fund future long-term operations, we
will need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including
capital market conditions, regulatory requirements and outcomes related to TLANDO, regulatory requirements related to our other
development programs, the timing and results of our ongoing development efforts, the potential expansion of our current development
programs, potential new development programs, the pursuit of various potential commercial activities and strategies associated
with our development programs and related general and administrative support. We anticipate that we will seek to fund our operations
through public or private equity or debt financings or other sources, such as potential license, partnering and collaboration agreements.
In March 2017, we entered into a Controlled Equity Offering Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald&nbsp;&amp;
Co. (&ldquo;Cantor&rdquo;) pursuant to which we may issue and sell, from time to time, shares of our common stock having an aggregate
offering price of up to $20.0 million through Cantor as our sales agent (the &ldquo;ATM Offering&rdquo;). However, even with the
ATM Offering, we cannot be certain that anticipated additional financing will be available to us on favorable terms, or at all.
Although we have previously been successful in obtaining financing through public and private equity securities offerings and our
license and collaboration agreements, there can be no assurance that we will be able to do so in the future. If we are unable to
raise sufficient capital to fund our planned business operations and the continued development of our product candidates, we will
have to reduce operations and expenses to conserve cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marathon Bar Corp. (&ldquo;Marathon Bar&rdquo;)
was incorporated on October 13, 2011, in the State of Delaware. On July&nbsp;24, 2013, Marathon Bar and MBAR Acquisition Corp.
(&ldquo;Merger Sub&rdquo;), a wholly owned subsidiary of Marathon Bar, and Lipocine Operating Inc. (&ldquo;Lipocine Operating&rdquo;),
a privately held company incorporated in Delaware, executed an Agreement and Plan of Merger (&ldquo;Merger Agreement&rdquo;). Pursuant
to the Merger Agreement, Merger Sub merged with and into Lipocine Operating and Lipocine Operating was the surviving entity. Additionally,
pursuant to the Merger Agreement, Marathon Bar changed its name to Lipocine Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 and our telephone number is (801) 994-7383. We maintain a website at
www.lipocine.com. Information contained in or accessible through our website does not constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Securities We May Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may offer shares of our common stock
and preferred stock, various series of debt securities and warrants to purchase any of such securities, either individually or
in units, with a total value of up to $150,000,000 million from time to time under this prospectus, together with any applicable
prospectus supplement and related free writing prospectus, at prices and on terms to be determined by market conditions at the
time of offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a
type or series of securities, we will provide a prospectus supplement that will describe the specific amounts, prices and other
important terms of the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">designation or classification;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">aggregate principal amount or aggregate offering price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">maturity, if applicable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">original issue discount, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">rates and times of payment of interest or dividends, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">redemption, conversion, exchange or sinking fund terms, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">ranking;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">restrictive covenants, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">voting or other rights, if any; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">important United States federal income tax considerations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A prospectus supplement and any related
free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this
prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will
offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement
of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell the securities directly to or
through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable
prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the names of those underwriters or agents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">applicable fees, discounts and commissions to be paid to them;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">details regarding over-allotment options, if any; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the net proceeds to us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Common Stock</I></B>. We may offer
shares of our common stock from time to time. Each outstanding share of common stock entitles the holder thereof to one vote per
share on all matters. Our bylaws provide that any vacancy occurring in the board of directors may be filled by the affirmative
vote of a majority of the remaining directors. Stockholders do not have preemptive rights to purchase shares in any future issuance
of our common stock. In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to receive,
ratably, the net assets available to stockholders after payment of all creditors. All of the issued and outstanding shares of our
common stock are duly authorized, validly issued, fully paid and non-assessable. Our common stock is described in greater detail
in this prospectus under &ldquo;Description of Capital Stock &mdash; Common Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Preferred Stock</I></B>. Our board
of directors has the authority under our amended and restated certificate of incorporation, without further action by our stockholders,
to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares
to be included in each such series, to fix the rights, preferences, privileges and restrictions of the shares of each wholly unissued
series, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference and sinking fund
terms, and to increase or decrease the number of shares of any such series (but not below the number of shares of such series then
outstanding). Our Preferred Stock is described in greater detail in this prospectus under &ldquo;Description of Capital Stock &mdash;
Preferred Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will fix the rights, preferences, privileges,
qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus
supplements in the certificate of designation relating to that series. We will incorporate by reference into the registration statement
of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred
stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplements
and any free writing prospectus that we may authorize to be provided to you related to the series of preferred stock being offered,
as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Debt Securities</I></B>. We may offer
debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible
debt. The debt securities will be issued under one or more documents called indentures, which are contracts between us and a trustee
for the holders of the debt securities. In this prospectus, we have summarized certain general features of the debt securities
under &ldquo;Description of Debt Securities.&rdquo; We urge you, however, to read the prospectus supplements and any free writing
prospectus that we may authorize to be provided to you related to the series of debt securities being offered, as well as the complete
indentures that contain the terms of the debt securities. Forms of indentures have been filed as exhibits to the registration statement
of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part, or incorporated by reference
from a current report on Form 8-K that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Warrants</I></B>. We may offer warrants
for the purchase of our common stock, preferred stock and/or debt securities in one or more series, from time to time. We may issue
warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached
to or separate from those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In this prospectus, we have summarized certain
general features of the warrants under &ldquo;Description of Warrants.&rdquo; We urge you, however, to read the prospectus supplements
and any free writing prospectus that we may authorize to be provided to you related to the particular warrants being offered, as
well as the complete warrant document or agreement that contain the terms of the warrants. Specific warrant documents or agreements
will contain additional important terms and provisions and will be filed as exhibits to the registration statement of which this
prospectus is a part, or incorporated by reference from a current report on Form 8-K that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Units</I></B>. We may offer units
consisting of common stock, preferred stock, debt securities and/or warrants to purchase any of such securities in one or more
series. In this prospectus, we have summarized certain general features of the units under &ldquo;Description of Units.&rdquo;
We urge you, however, to read the prospectus supplements and any free writing prospectus that we may authorize to be provided to
you related to the particular units being offered, as well as the unit agreements that contain the terms of the units. We will
file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a current
report on Form&nbsp;8-K that we file with the SEC, the form of unit agreement and any supplemental agreements that describe the
terms of the units we are offering before the issuance of the related units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THIS PROSPECTUS MAY NOT BE USED TO OFFER
OR SELL ANY SECURITIES UNLESS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NASDAQ Capital Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on The NASDAQ
Capital Market under the symbol &ldquo;LPCN&rdquo;. The applicable prospectus supplement will contain information, where applicable,
as to other listings, if any, on the NASDAQ Capital Market or other securities exchange of the securities covered by the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_019"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An investment in our securities involves
a high degree of risk. The prospectus supplement applicable to each offering of our securities will contain a discussion of the
risks applicable to an investment in our securities.&nbsp; Prior to making a decision about investing in our securities, you should
carefully consider the specific factors discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement,
together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or
incorporated by reference in this prospectus.&nbsp; You should also consider the risks, uncertainties and assumptions discussed
under Item 1A, &ldquo;Risk Factors,&rdquo; in our Annual Report on Form&nbsp;10-K for the fiscal year ended December 31, 2016,
and our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2017, June 30, 2017 and September 30, 2017, both
of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports
we file with the Securities and Exchange Commission in the future.&nbsp;&nbsp; The risks and uncertainties we have described are
not the only ones we face.&nbsp; Additional risks and uncertainties not presently known to us or that we currently deem immaterial
may also affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B>&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_020"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as described in any applicable prospectus,
prospectus supplement and in any free writing prospectuses in connection with a specific offering, we currently intend to use the
net proceeds from this offering primarily for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_021"></A>RATIO
OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK DIVIDENDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth, for each
of the periods presented, our ratio of earnings to fixed charges&nbsp;and the ratio of earnings to combined fixed charges and preferred
stock dividends for each of the periods indicated. You should read this table in conjunction with the financial statements and
notes incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nine<BR>
 months<BR>
ended <BR>
September <BR>
30,</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year ended December 31,</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2017</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2014</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Ratio of earnings to fixed charges (1)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Ratio of earnings to combined fixed charges and preferred stock dividends (1)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>(1)</SUP>For purposes of this ratio, earnings is defined
as net loss. Our only fixed charge is the interest within our rent expense. Our earnings were insufficient to cover fixed charges
in all periods presented, and therefore&nbsp;we&nbsp;are unable to disclose a ratio of earnings to fixed charges for all periods
presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_022"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of this prospectus, our certificate
of incorporation authorizes us to issue 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares
of preferred stock, par value $0.0001 per share. The following is a summary of the rights of our common and preferred stock and
some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, our registration
rights agreements and the Delaware General Corporation Law. Because it is only a summary, it does not contain all the information
that may be important to you and is subject to and qualified in its entirety by our amended and restated certificate of incorporation
and our amended and restated bylaws, a copy of each of which has been incorporated as an exhibit to the registration statement
of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated certificate of
incorporation and our amended and restated bylaws contain certain provisions that are intended to enhance the likelihood of continuity
and stability in the composition of the board of directors, which may have the effect of delaying, deferring or preventing a future
takeover or change in control of Lipocine unless such takeover or change in control is approved by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of September 30, 2017 there were 21,185,817
shares of common stock outstanding. In addition, as of September 30, 2017 there were: (i) 2,067,967 shares of common stock subject
to outstanding options; (ii) 272,000 shares of common stock subject to outstanding restricted stock units; and (iii) 896,020 shares
of common stock reserved for future issuance under our Amended and Restated 2014 Stock and Incentive Plan. Each outstanding share
of common stock entitles the holder thereof to one vote per share on all matters. Our bylaws provide that any vacancy occurring
in the board of directors may be filled by the affirmative vote of a majority of the remaining directors. Stockholders do not have
preemptive rights to purchase shares in any future issuance of our common stock. In the event of our liquidation, dissolution or
winding up, holders of our common stock are entitled to receive, ratably, the net assets available to stockholders after payment
of all creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All outstanding shares of common stock are,
and all shares of common stock to be outstanding upon the closing of this offering will be, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additional shares of authorized common stock
may be issued, as authorized by our board of directors from time to time, without stockholder approval, except as may be required
by applicable stock exchange requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent and registrar for our
common stock is American Stock Transfer &amp; Trust Company LLC. Their telephone number is 1-800-937-5449. Our common stock is
listed on The NASDAQ Capital Market under the symbol &ldquo;LPCN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of directors has the authority
under our amended and restated certificate of incorporation, without further action by our stockholders, to issue up to 10,000,000
shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such
series, to fix the rights, preferences, privileges and restrictions of the shares of each wholly unissued series, including dividend
rights, conversion rights, voting rights, terms of redemption, liquidation preference and sinking fund terms, and to increase or
decrease the number of shares of any such series (but not below the number of shares of such series then outstanding).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors may authorize the
issuance of preferred stock with voting or conversion rights that could have the effect of restricting dividends on our common
stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock or otherwise adversely
affecting the rights of holders of our common stock. The issuance of preferred stock, while providing flexibility in connection
with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing
a change of control and may adversely affect the market price of our common stock. As of September 30, 2017, no shares of preferred
stock were outstanding, and we have no current plans to issue any shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Future Preferred Stock</I></B>. Our
board of directors will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each
series that we sell under this prospectus and applicable prospectus supplements in the certificate of designation relating to that
series. We will file as an exhibit to the registration statement of which this prospectus is a part, or incorporate by reference
into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the
terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. This description
will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the title and stated value;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the number of shares we are offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the liquidation preference per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the purchase price per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the dividend rate per share, dividend period and payment dates and method of calculation for dividends;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the procedures for any auction and remarketing, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the provisions for a sinking fund, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any listing of the preferred stock on any securities exchange or market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">voting rights, if any, of the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">preemptive rights, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">restrictions on transfer, sale or other assignment, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">a discussion of any material or special United States federal income tax considerations applicable to the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When we issue shares of preferred stock
under this prospectus, the shares will be fully paid and nonassessable and will not have, or be subject to, any preemptive or similar
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The General Corporation Law of the State
of Delaware, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately
as a class on any proposal involving fundamental changes in the rights of holders of that preferred stock. This right is in addition
to any voting rights that may be provided for in the applicable certificate of designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Our Certificate of Incorporation
and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated certificate of
incorporation and amended and restated bylaws contain certain provisions that may have anti-takeover effects, making it more difficult
for or preventing a third party from acquiring control of Lipocine or changing our board of directors and management. According
to our amended and restated certificate of incorporation and amended and restated bylaws, the holders of our common stock do not
have cumulative voting rights in the election of our directors. The combination of the present ownership and control of 6% of our
issued and outstanding common stock by our executive officers and directors as a group as of September 30, 2017 and the lack of
cumulative voting, may make it more difficult for other stockholders to replace our board of directors or for a third party to
obtain control of the company by replacing our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delaware Anti-Takeover Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to Section 203 of the Delaware
General Corporation Law, or Section 203. Section 203 generally prohibits a public Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in
which the person became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">at or subsequent to the time of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of its stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of our outstanding voting stock that is not owned by the interested stockholder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, Section 203 defines a &ldquo;business
combination&rdquo; to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder and an
 &ldquo;interested stockholder&rdquo; as a person who, together with affiliates and associates, owns (or within three years, did
own) 15% or more of a corporation&rsquo;s voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>S</B>ection 203 could prohibit or delay
mergers or other takeover or change in control attempts not approved in advance by our Board of directors and, accordingly, may
discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock
at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Amended and Restated Certificate of Incorporation and
Amended and Restated Bylaws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provisions of our amended and restated certificate
of incorporation and amended and restated bylaws, which became effective following the closing of the Merger, may delay or discourage
transactions involving an actual or potential change of control or change in our Board of directors or our management, including
transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might
otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock.
Among other things, our amended and restated certificate of incorporation and bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">permit our Board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change of control); </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provide that the authorized number of directors may be changed only by resolution of our Board of directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provide that directors may only be removed, subject to any limitation imposed by law, by the holders of at least a majority of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&rsquo;s notice; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provide that special meetings of our stockholders may be called only by the chairman of our Board of directors, our chief executive officer or by our Board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amendment of any of these provisions
would require approval by the holders of at least 66 2/3% of the voting power of all of our then-outstanding common stock entitled
to vote generally in the election of directors, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 57; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_023"></A>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This section describes the general terms
and provisions of the debt securities that we may offer using this prospectus and the related indentures. This section is only
a summary and does not purport to be complete. You must look to the relevant form of debt security and the related indenture for
a full understanding of all terms of any series of debt securities. The form of debt security and the related indenture have been
or will be filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. See
 &ldquo;Where You Can Find More Information&rdquo; for information on how to obtain copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may issue senior or subordinated debt
securities from time to time in one or more series under one of two separate indentures, which may be supplemented or amended from
time to time. Senior debt securities will be issued under a senior indenture and subordinated debt securities will be issued under
a subordinated indenture. The senior debt indenture and the subordinated debt indenture are referred to individually in this prospectus
as the &ldquo;indenture&rdquo; and collectively as the &ldquo;indentures.&rdquo; This prospectus outlines briefly the provisions
of the indentures. The particular terms of a series of debt securities and the extent, if any, to which the particular terms of
the issue modify the terms of the indenture will be described in the accompanying prospectus supplement relating to such series
of debt securities. In some instances, certain of the precise terms of debt securities you are offered may be described in a further
prospectus supplement, known as a pricing supplement. The indentures are subject to and governed by the Trust Indenture Act of
1939, as amended, and may be supplemented or amended from time to time following their execution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The debt securities may be denominated and
payable in U.S. dollars or foreign currencies. We may also issue debt securities with the principal amount, interest or other amounts
payable to be determined by reference to one or more currency exchange rates, securities or baskets of securities, commodity prices,
indices or any other financial, economic or other measure or instrument, including the occurrence or non-occurrence of any event
or circumstance. Debt securities may bear interest at a fixed rate, which may be zero, or a floating rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of the debt securities may be issued
as original issue discount debt securities. Original issue discount securities bear no interest or bear interest at below-market
rates and will be sold at a discount from their stated principal amount. The prospectus supplement relating to an issue of original
issue discount securities will contain information relating to United States federal income tax, accounting, and other special
considerations applicable to original issue discount securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders may present debt securities for
exchange or transfer, in the manner, at the places and subject to the restrictions stated in the debt securities and described
in the applicable prospectus supplement and other offering material we will provide. We will provide these services without charge
except for any tax or other governmental charge payable in connection with these services and subject to any limitations provided
in the applicable indenture pursuant to which such debt securities are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders may transfer debt securities in
definitive bearer form and the related coupons, if any, by delivery to the transferee. If any of the securities are held in global
form, the procedures for transfer of interests in those securities will depend upon the procedures of the depositary for those
global securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will generally have no obligation to
repurchase, redeem, or change the terms of debt securities upon any event (including a change in control) that might have an adverse
effect on our credit quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 58; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_024"></A>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description, together with
the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the
material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase
common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently
or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to
or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer
under this prospectus, we will describe the particular terms of any warrants that we may offer in more detail in the applicable
prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement
may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth
in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from a current report on Form&nbsp;8-K that we file
with the SEC, the form of warrant document or agreement that describes the terms of the particular warrants we are offering before
the issuance of the related warrants. The following summaries of material provisions of the warrants are subject to, and qualified
in their entirety by reference to, all the provisions of the warrant document or agreement applicable to particular warrants. We
urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular warrants
that we sell under this prospectus, as well as the complete warrant document or agreement that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will describe in the applicable prospectus
supplement the terms relating to the warrants, including, if applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the offering price and aggregate number of warrants offered;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the currency for which the warrants may be purchased;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the dates on which the right to exercise the warrants will commence and expire;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the manner in which the warrant agreements and warrants may be modified;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">material United States federal income tax consequences of holding or exercising the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the terms of the securities issuable upon exercise of the warrants; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before exercising their warrants, holders
of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of the warrants may exercise the
warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and
paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement.
We will set forth in the warrant agreement or documents and in the applicable prospectus supplement the information that the holder
of the warrant will be required to deliver to the warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon receipt of the required payment and
the warrant documents properly completed and duly executed at the office of the warrant agent or any other office indicated in
the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all
of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining
amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities
as all or part of the exercise price for warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_025"></A>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description, together with
the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions
of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units
that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable
prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below.
However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security
that is not registered and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from a current report on Form&nbsp;8-K that we file
with the SEC, the form of unit agreement that describes the terms of the units we are offering, and any supplemental agreements,
before the issuance of the related units. The following summaries of material terms and provisions of the units are subject to,
and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable
to particular units. We urge you to read the applicable prospectus supplements related to the particular units that we sell under
this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may issue units comprised of one or more
debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so
that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the
rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that
the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will describe in the applicable prospectus
supplement the terms of the units, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any provisions of the governing unit agreement that differ from those described below; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provisions described in this section,
as well as those described under &ldquo;Description of Capital Stock,&rdquo; &ldquo;Description of Debt Securities&rdquo; and &ldquo;Description
of Warrants&rdquo; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each
unit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuance in Series</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may issue units in such amounts and in
numerous distinct series as we determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights by Holders of Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each unit agent will act solely as our agent
under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any
unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or
responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to
initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the
related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security
included in the unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We, the unit agents, and any of their agents
may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any
purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 61; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_026"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell the securities from time to
time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, directly to one or more purchasers,
or through any combination of these methods. The distribution of the securities may be effected from time to time in one or more
transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices related
to the prevailing market prices or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A prospectus supplement or supplements (and
any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the
securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the name or names of any underwriters or dealers, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the purchase price of the securities and the proceeds we will receive from the sale;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any over-allotment options under which underwriters may purchase additional securities from us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any agency fees or underwriting discounts and other items constituting agents&rsquo; or underwriters&rsquo; compensation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any public offering price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any securities exchange or market on which the securities may be listed.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Only underwriters named in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>By Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If underwriters are used in the sale, they
will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at
a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase
the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities
to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject
to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement.
Any public offering price and any discounts or concessions allowed or reallowed may change from time to time. We may use underwriters
with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of
any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>By Dealers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a dealer is utilized in the sale of any
securities offered by this prospectus, we will sell those securities to the dealer, as principal. The dealer may then resell the
securities to the public at varying prices to be determined by the dealer at the time of resale. We will set forth the names of
the dealers and the terms of the transaction in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>By Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell securities directly or through
agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe
any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent
will act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>By Direct Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may also directly sell securities offered
by this prospectus. In this case, no underwriters or agents would be involved. We will describe the terms of those sales in the
applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Underwriters, dealers and agents that participate
in the distribution of the securities offered by this prospectus may be deemed underwriters under the Securities Act, and any discounts
or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and
commissions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may authorize agents, dealers or underwriters
to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth
in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the
future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts
in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may provide agents and underwriters with
indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution
with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may
engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some or all of the securities we offer,
other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market
in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot
guarantee the liquidity of the trading markets for any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may enter into derivative transactions
with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If
the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered
by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third parties may
use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of
stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock.
The third parties in such sale transactions will be identified in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">One or more firms, referred to as &ldquo;remarketing
firms,&rdquo; may also offer or sell the securities, if the prospectus supplement so indicates, in connection with a remarketing
arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as agents for us. These remarketing
firms will offer or sell the securities in accordance with the terms of the securities. The prospectus supplement will identify
any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&rsquo;s compensation.
Remarketing firms may be deemed to be underwriters in connection with the securities they remarket.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any underwriter may engage in overallotment,
stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act.
Overallotment involves sales in excess of the offering size, which create a short position. This short sales position may involve
either &ldquo;covered&rdquo; short sales or &ldquo;naked&rdquo; short sales. Covered short sales are short sales made in an amount
not greater than the underwriters&rsquo; over-allotment option to purchase additional securities in this offering described above.
The underwriters may close out any covered short position either by exercising their over-allotment option or by purchasing securities
in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things,
the price of securities available for purchase in the open market, as compared to the price at which they may purchase securities
through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must
close out any naked short position by purchasing securities in the open market. A naked short position is more likely to be created
if the underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price of the securities
that could adversely affect investors who purchase securities in this offering. Stabilizing transactions permit bids to purchase
the underlying security for the purpose of fixing the price of the security so long as the stabilizing bids do not exceed a specified
maximum. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold
by the dealer are purchased in a covering transaction to cover short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any underwriters who are qualified market
makers on the NASDAQ Capital Market may engage in passive market making transactions in our common stock, preferred stock, warrants
and debt securities, as applicable, on the NASDAQ Capital Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M, during
the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market
makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a
passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent
bids are lowered below the passive market maker&rsquo;s bid, however, the passive market maker&rsquo;s bid must then be lowered
when certain purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Similar to other purchase transactions,
an underwriter&rsquo;s purchase to cover the syndicate short sales or to stabilize the market price of our securities may have
the effect of raising or maintaining the market price of our securities or preventing or mitigating a decline in the market price
of our securities. As a result, the price of our securities may be higher than the price that might otherwise exist in the open
market. The imposition of a penalty bid might also have an effect on the price of the securities if it discourages resales of the
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither we nor the underwriters make any
representation or prediction as to the effect that the transactions described above may have on the price of the securities. If
such transactions are commenced, they may be discontinued without notice at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on The NASDAQ
Capital Market under the symbol &ldquo;LPCN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 64; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_027"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dorsey &amp; Whitney LLP, Salt Lake City,
Utah will pass for us upon the validity of the securities being offered by this prospectus and applicable prospectus supplement,
and counsel named in the applicable prospectus supplement will pass upon legal matters for any underwriters, dealers or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_028"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of
Lipocine Inc. as of December 31, 2016 and 2015, and for each of the years in the three-year period ended December 31, 2016, have
been incorporated by reference herein in reliance on the reports of KPMG LLP, independent registered public accounting firm, incorporated
by reference herein, and upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_029"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a reporting company and file annual,
quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement
on Form S-3 under the Securities Act with respect to the securities we are offering under this prospectus. This prospectus does
not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For
further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration
statement and the exhibits and schedules filed as a part of the registration statement. You may read and copy the registration
statement, as well as our reports, proxy statements and other information, at the SEC&rsquo;s Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying
cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The SEC maintains
an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC, where our SEC filings are also available. The address of the SEC&rsquo;s web site is &ldquo;http://www.sec.gov.&rdquo;
We maintain a website at www.lipocine.com. Information contained in or accessible through our website does not constitute a part
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 65; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_030"></A>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information that we file with it into this prospectus, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus.
The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with
the Commission will automatically update and supersede information contained in this prospectus and any accompanying prospectus
supplement.&nbsp; We incorporate by reference the documents listed below that we have previously filed with the Commission:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417012930/v460000_10k.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form 10-K for the year ended December 31, 2016;</A></TD></TR>
<TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;<FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417022853/v464712_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Our
    Definitive Proxy Statement filed on Schedule 14A on April 28, 2017;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;<FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Our
    Quarterly Reports on Form 10-Q for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417024980/v465087_10q.htm" STYLE="-sec-extract: exhibit">March 31, 2017</A>,
    <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417040693/v471572_10q.htm" STYLE="-sec-extract: exhibit">June 30, 2017</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417057030/tv477771_10q.htm" STYLE="-sec-extract: exhibit">September 30, 2017</A>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;<FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Our
    Current Reports on Form 8-K filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417004858/v457997_8k.htm" STYLE="-sec-extract: exhibit">January 31, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417004973/v458042_8-k.htm" STYLE="-sec-extract: exhibit">January 31, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417012942/v461111_8k.htm" STYLE="-sec-extract: exhibit">March 6, 2017 (only with respect to item 8.01)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417021626/v464818_8-k.htm" STYLE="-sec-extract: exhibit">April 24, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417029842/v467942_8-k.htm" STYLE="-sec-extract: exhibit">May 26, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417032331/v468937_8k.htm" STYLE="-sec-extract: exhibit">June 13, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417033029/v469221_8k.htm" STYLE="-sec-extract: exhibit">June 19, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417033918/v469401_8-k.htm" STYLE="-sec-extract: exhibit">June 26, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417034487/v469863_8-k.htm" STYLE="-sec-extract: exhibit">June 28, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417036127/v470501_8-k.htm" STYLE="-sec-extract: exhibit">July 7, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417036285/v470560_8-k.htm" STYLE="-sec-extract: exhibit">July 10, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417040991/v472588_8k.htm" STYLE="-sec-extract: exhibit">August 8, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417041401/v472596_8-k.htm">August 9, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417042629/v473147_8k.htm" STYLE="-sec-extract: exhibit">August 14, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417047309/v474863_8-k.htm" STYLE="-sec-extract: exhibit">September 8, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417048756/v475488_8k.htm" STYLE="-sec-extract: exhibit">September 20, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417048975/v475583_8k.htm" STYLE="-sec-extract: exhibit">September 21, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417049353/v475678_8k.htm" STYLE="-sec-extract: exhibit">September 25, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417052919/tv477175_8k.htm" STYLE="-sec-extract: exhibit">October 18, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417053962/tv477696_8k.htm" STYLE="-sec-extract: exhibit">October 25, 2017</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417057032/tv478656_8k.htm" STYLE="-sec-extract: exhibit">November 8, 2017 (only with respect to item 8.01)</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420417059844/tv479797_8k.htm" STYLE="-sec-extract: exhibit">November 17, 2017</A>; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;<FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><A HREF="http://www.sec.gov/Archives/edgar/data/1535955/000114420414016287/v371993_8a12b.htm" STYLE="-sec-extract: exhibit">The description of our common stock, which is contained in the Registration Statement on Form 8-A, as filed with the SEC on March 18, 2014</A>, including any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
</TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also incorporate by reference into this
prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act,
excluding, in each case, information deemed furnished and not filed until we sell all of the securities we are offering or the
termination of the offering. Any statements contained in a previously filed document incorporated by reference into this prospectus
is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus,
or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will provide to each person, including
any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the
information that has been incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits
that are specifically incorporated by reference into such documents. Requests should be directed to: Lipocine Inc., Attention:
Investor Relations, 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 and our telephone number is (801) 994-7383.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$150,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Lipocine Inc.</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock,
Preferred Stock,<BR>
Debt Securities,<BR>
Warrants and Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,084,034 Class A Units each consisting
of one Share of Common Stock and&nbsp;one-half of one Common Stock Purchase Warrant </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(and 5,042,017 Shares of Common Stock
Issuable Upon Exercise of the Common Stock Purchase Warrants)</B>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="tm209716-1_424b5img01.jpg" ALT="" STYLE="width: 330px; height: 102px"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROSPECTUS SUPPLEMENT&nbsp;</P>



<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Roth Capital Partners</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">February 25, 2020</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm209716-1_424b5img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm209716-1_424b5img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !F 4H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MJ&9U5>2V<K]TD-RV!T(X)X//?/:N8LO&OA&[OSIMKXGT2XU 2I;_ &&/5[.:
MY,\BJZ0K MP[O*4(;:BEE4C=C(H ZVBFJZN RG((##J.#G!P0",X/4=J&=5^
M\<?F?Y"@!U%5Y[NUMHY9;BXB@BAB:>:65UCCBA3AY)'8A453U+$5SUCXL\,Z
MO<S6VDZ_IFJ7$(W2V^G:G;WDL:X'S&*WG=PO/7;@$XS0!U-)D>H_,5R-SXT\
M,V4\EI>>)M!M+F&3RI+:ZU?3X+B.0)OV212RK(K!/F.5_&H!X]\"GA/&/A5F
MP64+K^E$_+D@\71]/?/H: .VHKE+7QEX9NG"P>)O#\^#@B/6-.8\G' 6;).2
M.!WKH8[RUGB\ZVN;>XCY'F0S)+'Q][+QLRC:.3S0!:HJ%9LLRMA2@!8<Y&[!
M7J,$$9Y&0",'!XIQFC&<N!@%B<'& 0.N,9R1@9R>P.#0!)14+7$*!BTBJ%QO
MSGY,J&RXQE!M8$EL  C)%>3>+_CS\&_ <_D>+_BIX$\-2%&<1ZQXCTVT8"/A
M\^9*0"IZJQ#9XV\4 >OTF1ZC\Q7SKI7[5_[.&N3Q6ND?'3X8ZC<3OY<45KXJ
MTR1W<_P@!^#]<5[AIVK:5K%JEYI6HV&IVTR>8ESI]U!>1.&4MN5[=Y!@CY@>
M 1@B@#;HJ(3PLNY949<*=P8$8<X7D$_>/ ]:>'4C(92,9X(/% #J*C\Z+&[>
MH7<%R>!N/0<]S2-/"F[=(@" ER3PH #$L>@ !!Y- $N1ZTF0.I _&O)O%WQN
M^$/@*98O&/Q.\#>%Y9BQ2/6_$FF6#N,Y! GF'W0PW9QMRN>JUQEA^UK^S-JD
MZVUC\=_A3?7+N(TBA\8Z.\CL3@(@$XW$MD#;G)/6@#Z-R/445SFF^(='U^V@
MO-"U;2]5M)AN@GTV^M;N*4%B-R-#(X8 J02O(.>0<XWA-'M!9@#D*P_N,?X6
MZ[.<_>Q]: ),CU'YBEKGM4\1Z'HJ)-K&H:=I4,LODQ3ZE<0V<,LIY")+<-&C
MLPY&&Y^M)!XCT&ZL&U2VU&RGTQ(FF?48KR&:Q2%0A:1[E93 (U$L98LX4!QD
MXS@ Z*BN'M?'7@O4+B&SL/$V@W=W<K$]O!::EI[S3)-M:-HO*N69A(K#!7/!
MP<'('7P2*25&_*EE(8YP0<D$=C@CDYXQ@G)H LT4F1G&><9Q[=,TCMM4MZ#]
M>WZT .HKE-5\7Z!H<RP:WKVCZ/,\;3)#J5_:V3O#&55Y46X=2Z*S %ES\Q(
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MW]SI5[:&XU+3_L\MG-*8PEJ^A1F)"IR)6V@J6Q_HY/U3_?'\FK_-0_X)Q_\
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M$CK) 24<-MN%(5D)R-RL5(PRDUY-\>"A_P""_E@%!24?&_PI$)EY96;3XSD
MD#'<]^.A)-?W^NH9E_O?/L)"D CD9X#8SS\K*>Q/.0 ?P@>(?^"&O_!5?P18
M-J_AWXXWWB2]MU\Y+#2O&OBNRN(94(9EA:2_?<X&\KA&5R I&":X?X1?\%2/
M^"D?_!-OXI0?#3]JNVUWQMX/TS5+;3+WPSXUMYEOFT>QC5IY]!U.*UC35F:U
M!D>5IYKE,*9 92<_WV30NAD93$@>/@K&^XR@C#-^] "JY5OERQ (/3G\;O\
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M\J15/., =?ZH/^"<7_!,KX,?L)_#'0+&T\,:/KWQ@O=-67QEX^OK);F_>ZN
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M6O GP5\$Z]\0_B-X@L_#/A#PS:7&H:KJ%_-%;XCM8GG>.W$O,CL"JH(U9@2
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M7(N8'@D@?SH7:* APYDC!E\P#" #G^._]N[_ (((_M!>!OV@=.^+_P#P3O\
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MXH((_P#!HH)[_= )_A XK^Z$JI9CM'4CJO8X[QD]NY/UH$:D X3D \E,\_\
M;*@#^%P?\$"?^"I#':_[0&G(C?*[GQ1XD8*AX9BJZF68!23@#)Z8K[2_X)\?
M\$@OV_/V<_VL?AW\8_C!\9+/Q1X'T!]035]#@UO7KZ%5O;>ZQ.MA-?2Q7,ML
MWEQQ;XV&)24&]01_6F(ER.%ZCHRYZ]L1@_D0?0@\TXPJ1P.ZYR205# L,>ZY
M'/'/- '\COQM_8._:#O?CAXEG'@C7?$VKZCXWUZ]MM>&IW!T/Q3I?B+5Q>V.
MH:\KW.Q'T6WBACAB5HY(HRT6%)X_J3^!WAG7O!7P;^$O@SQ3<"\\2>$?AAX
M\,^(;U,F*^U[0/">CZ3K%W 2[N(IM0L[B1 _+[_,#."&KT5[21I8I 8<0O\
M(JKY;+&!A4$H5WP< LN ,]#P*MQQA"S=&8G/S,P^N6QS]  ,XYQD@$M%%% !
M1110!'(<&/WD _,-7^:G_P $Y/\ E+9\&1SS\9_$D>>WRZWXCGS^/VD+CMY9
M;/S +_I5R]8O^NJ_R:O\U3_@G)_REM^#'_9;/$W_ *=-9H _TJ8.0Q]2O'_;
M-#U_'TJ>H+?[A^J_^BXZGH ^6OVU/^35?C__ -DVUO\ ]$M7\>7_  ;2?\GM
M?&;_ +)_JW_I3=U_8;^VI_R:K\?_ /LFVM_^B6K^/+_@VD_Y/:^,W_9/]6_]
M*;N@#ROX\C9_P7\L7ZX^.OA'CIUTQ#UY]*_O^,B@[CD;&D7&.6)SP,X[<^AR
M "2<5_ %\>AN_P""_-@/[WQW\)#\M-C _G7]]VH1@HX,IB#I<$RA=QB^1AOV
M '?L'S;<%FVX'7% $US<Q;O)!+3!=[11@NR1D@AW(&U3A1\N3DG )'S5^'__
M  7._;<^'W[.?[)WCOX;#6[:?XI?%C1YO"6@>';:ZA?4([*\\O\ M#4)[>-;
MADMTMR-S2&%H@P<[@=I_.;_@HO\ &_\ X+9? ?XNZMX$^&<NL>./AKXNO+I_
M!NK_  Y\)6NIW<>G79D-IIT]V8WDM[N*/89&EV%%1R2"!7P7^S]_P1:_;S_;
M:^*<7Q*_;,O=?\(>%KW5H-4UR?Q]KYD\53P2^6\UMX=L0TJV<$JJ4GA,)4#Y
M7X   .=_X)F67B/]G3_@GI^WC^UF;>[T]M7T*U^$'@^_D\^$?:=?DBL[^[6-
MD07,4LUQ)B6.0;2HAW$R"6/Z._X-E/V<M*^('Q4^,/[3GB&TM-4O? <<7A?2
M);B O%;^)=5GU*^O;@^=/*QN;9+F#RBB+D[V:0*R!?UA_P""N_[.7A3X%_\
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M06@^*==^%6F:M]@U;1+V*\/B3X=W,<BQ7-K8#44!GT^)P[B<-< J5CC*H=H
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MRIIQ5[<UE-NUGIN^Y^8W[0'[=/QK\,?M%74?PST?3=4_9\^#&J:-X=^-.KW
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M":TD!"X/7+?JQ(_2O)/U<=1110 4C#<"#SG'Z'/H?Y444">B?HRK/$JKNP,
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M .75-/JXP2;?=M=?/\R9H2%##:1DEN2H&W"C:FTC+-]XE@< $[CP'&!RK-O
M#)TQT& < 8&. ,<^@SQFBBE+WHJ+;LK6L[/1I[_+\^X*G&+J-*SJJ,)_X8JR
MMIIHM6M6!ADW?PG9@#]XZJ3(0&)4(0IC7/E8)RV"0O6G(D@(=E09.XJLCD @
ME< &-<J58-@XPP'L:**5G_-+YR;*M%6M""\U"*:W>EEH6$4H=HP5.YNO(Z<8
1QSR3SGTXJ2BBF,**** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
